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Abstract 
Teleglaucoma is a screening device that remotely detects glaucoma cases at earlier 
stages using electronically-transferred stereoscopic digital imaging. Thus, patient 
wait and travel times are reduced, as well as, patient load in ophthalmic clinics. The 
purpose is to synthesize literature to evaluate teleglaucoma: its diagnostic accuracy, 
the healthcare system benefits, and its cost-effectiveness. A systematic review was 
conducted with published and unpublished studies. A meta-analysis was conducted 
to provide estimates of diagnostic accuracy, diagnostic odds ratio, and the relative 
percentage of glaucoma cases detected. Using Markov Modelling, a cost-
effectiveness analysis was conducted. Of 11237 studies reviewed, 45 were included. 
Teleglaucoma was more specific and less sensitive than in-person examination. The 
pooled estimates of sensitivity was 0.832 [95% CI 0.770, 0.881] and specificity was 
0.790 [95% CI 0.668, 0.876]. The ICER calculated for teleglaucoma was 
$27,460/QALY. In conclusion, teleglaucoma was found to be more cost-effective 
than in-person examination in rural areas.  
 
Keywords 
Teleglaucoma, tele-ophthalmology, screening, digital photography, diagnostic 
accuracy, glaucoma, ophthalmology, systematic review, meta-analysis, cost-
effectiveness analysis 
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1 Introduction 
The burden of vision loss on the Canadian economy is $15.8 billion per year in 
which 55% is allocated to direct health care costs.1 Sixty-five per cent of adults with 
partial or full vision loss are unemployed, which translates to $4.06 CAN billion annually 
of lost earnings.1 In the United States, vision loss costs over $35 billion for direct costs 
and loss of productivity.2 Glaucoma is the major eye disease leading to irreversible 
vision loss. The economic burden of glaucoma alone on the American economy is $2.9 
billion.2  
Glaucoma tends to be detected at later stages of the disease when glaucoma 
has advanced into vision impairment due to peripheral visual field loss. Patients have 
“tunnel vision,” but may have perfect central vision. As a result, patients may not notice 
visual field loss until advance stages of disease. Detection of glaucoma at earlier stages 
is important for treatment and to prevent the progression of disease.3  
Teleglaucoma is a screening device that can help detect glaucoma patients at 
earlier stages by remotely identifying glaucoma via electronic transmission of high-
resolution stereoscopic fundus photographs. Teleglaucoma is hypothesized as a more 
efficient way of managing glaucoma in rural areas, such as Alberta. Currently this 
technology is validated for use in diabetic retinopathy, but recent research has 
assessed its performance for glaucoma.4 Teleglaucoma has the potential to reduce 
patient wait and travel times in rural areas as well as reduce the patient load in 
ophthalmic clinics. The first objective of this study is to synthesize the literature on 
teleglaucoma through a systematic review and conduct a meta-analysis to generate the 
diagnostic accuracy of teleglaucoma. The second objective is to assess the cost-
effectiveness of teleglaucoma relative to in-person examination (standard of care). 
1.1 Structure of thesis document  
This thesis is presented in Integrated-article format in compliance with the standards 
outlined by Western University School of Graduate and Postdoctoral studies. Chapter 2 
describes the background literature on glaucoma and teleglaucoma. The thesis consists 
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of two manuscripts. The first manuscript is “The effectiveness of teleglaucoma versus 
in-person examination (Systematic Review and Meta-Analysis)” and it comprises 
chapter 3. The second manuscript is “The cost-effectiveness of teleglaucoma versus in-
person examination” and it comprises chapter 4. The first objective is addressed in 
chapter 3 and the second objective is addressed in chapter 4. Chapter 3 has recently 
been published in a peer-reviewed journal and publisher permissions have been 
granted to include the paper in this thesis (Appendix 1).5 Portions of chapter 4 have 
been conditionally accepted for publication and is now under second review with PLoS 
ONE journal.6 Chapter 5, the integrated discussion, summarizes the main results of the 
thesis and generates conclusions. 
1.2 Literature Cited 
1. Canadian National Institute for the Blind (CNIB) and the Canadian 
Ophthalmology Society (2009) Costs of vision loss in Canada. Access 
Economics Pty Limited Available: http://www.cnib.ca/eng/cnib%20document%2
0library/research/covl_full_report.pdf. 
 
2. Rein DB, Zhang P, Wirth KE et al. (2006) The economic burden of major adult 
disorders in the United States. Arch Ophthalmol Dec; 124(12): 1754-60.  
 
3. Hatt S, Wormald R, Burr J (2006) Screening for prevention of optic nerve 
damage due to chronic open angle glaucoma. Cochrane Database of Systematic 
Reviews Issue 4. Art. No.: CD006129. DOI:0.1002/14651858.CD006129.pub2. 
 
4. American Academy of Ophthalmology. Diabetic Retinopathy Preferred Practice 
Pattern Guidelines. San Francisco, CA; 2008:39. Available at: 
http://one.aao.org/CE/PracticeGuidelines/PPP_Content.aspx?cid=d0c853d3-
219f-487b-a524-326ab3cecd9a. 
 
5. Thomas S-M, Jeyaraman MM, Hodge WG, Hutnik C, Costella J, Malvankar-
Mehta MS. (2014) The Effectiveness of Teleglaucoma versus In-Patient 
Examination for Glaucoma Screening: A Systematic Review and Meta-Analysis. 
PLoS ONE 9(12): e113779. doi: 10.1371/journal.pone.0113779. pmid:25479593 
 
6. Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness 
Analysis of Teleglaucoma Screening Device. PLoS ONE (under second review 
2015 June 7).  
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Chapter 2 Literature Review, Thesis Rationale, and Thesis 
Objective 
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2.1 Literature review 
2.1.1 Natural history of glaucoma 
Glaucoma is an ophthalmic disease characterized by death of the optic nerve 
from excess fluid pressure in the eye. Increased pressure occurs when the trabecular 
meshwork can no longer drain excess fluid. Glaucoma is not a singular disease, but a 
collection of ophthalmic diseases with various clinical presentations that causes 
progressive optic neuropathy. They ultimately end in irreversible vision loss. Glaucoma 
is primarily categorized as either open or closed-angle glaucoma:  
Open-angle glaucoma (OAG) is the most common type of glaucoma; 90% of 
glaucoma cases are open-angle.1 It is caused when the drainage canals clog and 
intraocular pressure rises. The angle between the cornea and iris becomes wide 
and open. Open-angle glaucoma is also called primary or chronic glaucoma. It 
slowly develops and symptoms are not noticed until advanced stages. Glaucoma 
presents as mild, moderate, and severe stages. The outer nerves of the eye are 
damaged first and causes vision loss starting at the edges of the eye. As it 
progresses, vision is lost inward producing “tunnel vision”. Because of this, many 
glaucoma patients do not notice their vision loss until the advanced stages of 
glaucoma. It is estimated that 50% of those with glaucoma are unaware of their 
disease status.2 The focus of this thesis is OAG. 
Close-angle glaucoma is also caused by blocked drainage canals and results in 
increased intraocular pressure. The angle between the iris and cornea becomes 
narrow or closed. Unlike open-angle glaucoma, it develops quickly and vision 
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loss is very noticeable. Closed-angle glaucoma requires immediate medical 
attention.1   
2.1.2 Risk Factors 
Intraocular pressure 
Intraocular pressure (IOP) is one of the main characteristics of glaucoma. Normal 
IOP are pressure levels that do not lead to optic nerve head damage and average 
between 12-22 mm Hg.3 As it is measurable, it is a quantitative measure used to 
determine glaucoma, but it cannot solely be used for diagnosis. IOP is affected by 
several factors including genetics, environment, physiology, ethnicity, refractive error, 
and diurnal and postural variations.1,4, These factors on their own can be considered 
risk factors for glaucoma. Several genetic studies such as the Blue Mountains Eye 
study and Beaver Dam Eye Study have identified chromosomal locations responsible 
for fluctuations in IOP.1,5,6 Links between myopia and closed-angle glaucoma in adults 
are not definite; some studies have reported either positive or no associations.1 One of 
the main factors affecting IOP and contributing to glaucoma is systemic conditions such 
as diabetes mellitus, and hypertension. Smoking, drug use, and dietary exposures can 
affect IOP. Smoking can lead to vasoconstriction and increased episcleral venous 
pressure. Use of anesthesia drugs (eg. ketamine), illicit drugs (eg. LSD), and systemic 
medications (eg. corticosteroids, anticholinergic agents, sulfonamides) may elevate  
IOP.1,4 Dietary exposures have not been studied thoroughly, but associations have 
been seen between caffeine consumption and increased IOP. Also, consumption of 
fruits, vegetables, and omega-3 fatty acids may reduce IOP.1  
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Age and Ethnicity 
IOP tends to increase as people age naturally. Specifically adults older than 50 
years are at higher risk of glaucoma.4,7 The growth of crystalline lens increases as 
people age. This causes the anterior chamber to become crowded and closes the angle 
within the eye. The risk of glaucoma increases after the age of 40 years.4 The Baltimore 
Eye Survey found those who are 70 to 79 of age have a 3.5 times higher prevalence 
than those in between 40 to 49 years of age.4,8 Edgar et al reported in those aged 50-59 
years, the prevalence of open-angle glaucoma in Black populations was 4.6%, in Asian 
populations was 1%, and in Caucasian populations was 0.8%.9 There was an increased 
prevalence in all races with increased age: for ages 60-69 years, the prevalence was 
7.2% in Black populations, 1.6% in Asians, and 1.6% in Caucasian populations, and for 
ages 70-79 years the prevalence was 16%, 3%, and 6%, respectively.9 In older age 
groups, women tend to have greater IOP than men specifically after the onset of 
menopause.9      
 Ethnicity can affect IOP. Black populations have been found to have higher IOP 
and at greater risk for open-angle glaucoma.1,2,9 The Baltimore Eye Survey found that 
black populations have three to four times greater prevalence than Caucasians.8,9 
Nonetheless, studies have found Asian populations have increased risk of closed-angle 
glaucoma.9,10 Further trends based on ethnicity are detailed in the Epidemiology 
section.    
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2.1.3   Epidemiology 
Glaucoma is the leading cause of permanent blindness in Canada affecting more 
than 400,000 Canadians and 67 million people worldwide.2 Glaucoma is accountable for 
14% of all blindness cases.1  
Over the past decade there has been several population-based prevalence 
surveys of glaucoma globally.1,5,6,8 Of individuals aged 30 years or more, the prevalence 
of open-angle glaucoma ranges from 0.03% in China to 8.76% in St. Lucia.9 The 
prevalence of glaucoma is increases as people get older. Glaucoma is more prevalent 
in certain races. In Caucasian populations, the prevalence of open-angle glaucoma in 
those older than 40 years, is approximately 2%.9 However, it has been reported that 
Caucasians of comparable age groups have the same prevalence.9 In contrast, there 
was higher prevalence in similar age groups reported in Black populations in the 
Caribbean and North America.9 In North America, the highest prevalence is seen in the 
African-American population, at 8%.9 The age-adjusted rates were 4.3 times higher in 
African-Americans than Caucasians Americans.9 In addition, the age of onset is earlier 
in African-Americans than in Caucasian Americans.9 The prevalence of glaucoma is 
higher in Black Caribbeans than in African-Americans and black populations in Africa. 
Specifically, Caribbean countries such as St. Lucia and Barbados have reported the 
highest prevalence rates within the Caribbean.9,11 Significant glaucoma studies were 
completed in these countries such as the Barbados Eye Study.9,11 
In Asian populations, closed angle glaucoma are more common with a 
prevalence of 1%, while the prevalence of open-angle glaucoma is only 0.31%.9 
9 
 
 
 
However, variability has been reported. In Japan, the prevalence of open-angle 
glaucoma is greater than closed-angle glaucoma (2.53% versus 0.08% respectively).9  
The prevalence differs also for open-angle and closed-angle glaucoma. Open-
angle glaucoma is most common form of glaucoma in European, Africans, and North 
Americans.9     
The incidence of glaucoma is 0.04% and 4 out of every 10,000 persons at any 
given time will develop glaucoma.4 Studies have reported increased incidence with age: 
the five year incidence for those aged 55 years was 0.2% and it increased to 1% for 
those aged 75 years.9,12,13 Another study reported the annual incidence in those aged 
60-69 years was 12 per 10,000, in those aged 70-79 years incidence was 28 per 
10,000, and for those aged 80 years and older incidence was 82 per 10,000.4 
Specifically for black populations, the 4-year incidence reported was 55 per 10,000.4    
2.1.4 Clinical Assessment of Glaucoma 
Glaucoma diagnosis requires several diagnostic tests and imaging based on the 
following key characteristics of glaucoma: visual field, intraocular pressure, and optic 
nerve head. Each of the key characteristics of glaucoma and the required diagnostic 
tests are described in details below. 
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Visual Field 
Changes in visual field can be used to help detect glaucoma. Visual field loss in 
an eye that previously did not have visual field loss can indicate glaucoma. Also, 
progressive visual field loss in an eye with previous loss is an important factor. Visual 
field defects associated with OAG glaucoma are paracentral defects, arcuate defects, 
and nasal steps, as well as, depression in sensitivity, blind spot baring, and increased 
blind spot. The main detection technique used is visual inspection followed by 
comparison to normal visual field charts. Visual field loss is scored using the Glaucoma 
Hemifeld Test (GHT) or Humphrey Visual Field Analyzer (HFA).4  
Intraocular Pressure (IOP) 
IOP is measured using a tonometer. Applanation tonometry uses the Inbert-Fisck 
law which states IOP is equal to the weight applied to the cornea divided by the 
applanated area.1 There are two main tonometers: indentation and applanation. 
Indentation tonometer has a truncated cone shape and it displaces larger intraocular 
volume. Empirical data is used to create a conversion table to measure the IOP. The 
second type, the applanation tonometers, has a flattened shape deformation and the 
relationship to the IOP can be used to measure the IOP. The applanation tonometer 
measures the force that is required to flatten the corneal surface area. This is called the 
Goldman applanation tonometer. The Goldman applanation tonometer is widely used 
for measuring IOP. It is attached to a slit lamp and it is used to display the circular area 
of the cornea into semicircles.1  
11 
 
 
 
Another classification of tonometers are contact and non-contact tonometers. 
The Goldman applanation tonometer is a contact tonometer. The probe of the 
tonometer comes into contact with the cornea and as a result a topical anesthetic is 
used. The anesthetic is applied as an eye drop to the surface of the eye. An example is 
proxymetacaine.1 
Non-contact tonometers do not come into contact with the eye and instead uses 
a puff of air to deform the cornea. It determines the time and the force of the air-puff that 
is needed to flatten the cornea. It uses an electro-optical system to detect applanation. 
The force detected is used to estimate the IOP. Historically, the accuracy of non-contact 
tonometers have been incomparable to contact tonometers and thus, it was a 
convenient method for screening IOP. With advances in technology, however, current 
non-contact tonometers have correlated higher with the contact tonometers.1    
Optic Nerve Head  
The optic nerve is responsible for sending visual information from the eye to the 
brain and it is located at the back of the eye. The optic nerve head, also known as the 
optic disc, is the main pathological feature associated with glaucoma. It is the distal 
portion of the optic nerve, which extends from the retinal surface to the myelinated 
portion of the optic nerve.1 Retinal nerve fibers converge upon the optic nerve head 
which continues to the brain. The optic nerve head is susceptible to elevation of IOP. 
Progressive atrophy of the optic nerve head and loss of optic nerve fibers characterize 
glaucoma. The optic nerve head is normally shaped with a vertical ovoid referred to as a 
cup. The relationship between the diameter of the cup and the diameter of the whole 
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optic nerve head is used to diagnose glaucoma. This relationship is called the cup-to-
disc ratio (CDR).4 Glaucoma increases the size of the cup in a vertical oval-type pattern 
thereby increasing the CDR. Defects of the optic nerve are called cupping or a cupped 
nerve. One issue with using the CDR is that even within healthy eyes the values may 
range. One source reported the CDR of a healthy eye as approximately one third.16 
Another reported the average horizontal and vertical CDR as 0.5 and 0.42 respectively.4 
There are specific variations within race where African-Americans have significantly 
larger CDR than Caucasians.4  
Stereoscopic photos of the optic nerve are taken to evaluate for glaucoma. In 
addition to the CDR, the ophthalmologist uses the neuroretinal rim and the nerve fiber 
layer (NFL) of the optic nerve to determine optic nerve damage. Specifically, the 
thickness of neuroretinal rim and NFL should be greatest inferiorly and then the 
superior, nasal, and temporal rim; this is known as the ISNT rule.4 Deviation from this 
rule is a sign of potential glaucoma. Notching of the neuroretinal rim and/or a thin or 
sloped temporal rim are also associated with glaucoma. Thinning of the NFL can be 
associated with hemorrhaging. Disc hemorrhaging is seen in 40% of all glaucoma 
patients.4 This occurs usually before the neural rim notching or nerve fiber layer and 
visual field defects. The hemorrhaging is a result of the glaucomatous damage rather 
than a cause. Another sign of glaucomatous damage is the asymmetry of the optic 
nerve head between the eyes. Healthy eyes will have no more than a 0.2 difference 
between the CDR of the right and left eye.4    
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The traditional instrument for physically examining the optic nerve is the direct 
ophthalmoscope. However, it can only generate two-dimensional images, which are 
difficult to assess surface contours. Slit-lamp bio-microscope with handheld lens is the 
preferred instrument to physically examine the optic nerve.1,4 Additionally, optic disc 
stereophotography is used to monitor changes of the optic nerve by comparing older to 
recent photographs. Optic nerve head hemorrhaging, notching, neuroretinal rim loss, 
and vessel barring can all be seen with optic disc stereophotography.  
Optic nerve imaging uses technologies called GDx nerve fiber analyzer, 
Heidelberg Retinal Tomography (HRT), and Optical Coherence Tomography (OCT). 
GDx nerve fiber analyzer is a scanning laser polarimetry and it measures the 
peripapillary retinal nerve fiber layer thickness. It sends laser beams to the posterior 
retina and it uses the changes in the retardation of the reflected beam for creation of a 
high-resolution image of the optic nerve and peripapillary retina. This techniques 
measures the retinal nerve fiber layer (RNFL) thickness. A graphical plot of the RNFL 
thickness around the optic nerve, called the double hump, is determined along a 3.2 
mm diameter 8-pixel wide circle.4,15,16 In healthy eyes, the superior and inferior poles 
have the largest RNFL thickness compared to the nasal and temporal poles.4,15,16    
Heidelberg Retinal Tomography (HRT) uses scanning laser tomography to 
produce 3-dimensional high-resolution image of the optic nerve.17 HRT provides precise 
measurements of optic nerve head parameters that can be used to identify nerve fiber 
damage and loss. It uses laser beams to shine light and scan different areas of the 
retina.18 The computer develops a calculated image that is used to produce 
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measurements of morphometric parameters of the disc.1 This information is used to 
classify the nerve as normal or glaucomatous and to measure the disease progression. 
A reference ring is placed on the image to define the retinal surface. The cup is the 
structure located below the reference plane and the rim is the structure above the 
reference plane or within the contour lines. To measure the RNFL thickness, HRT uses 
the distance between the reference plane and the retinal surface.4,18 Moorfields 
regression analysis uses the ratio of the rim area to the disc area to determine the 
appearance of the optic nerve head as “normal,” “borderline,” and “outside normal 
limits.”1,4     
Optical Coherence Tomography (OCT) is an imaging technique that applies 
the concepts of interferometry. It uses a low-coherence infrared diode light source that 
splits into two beams and  travels perpendicular to each other. The light is then reflected 
with the eye and intersects with the reference beam. The point of intersection creates 
an interference signal, which is detected by the interferometer. These signals are then 
used to create a cross-sectional image of the retina. The RNFL thickness is measured 
by the difference in the delay of backscattered light from the RNFL inside the imaged 
tissue.1 This test is non-invasive, involves no contact, and is trans-pupillary. With OCT, 
a linear scan of the retina is performed in 1 second while the pupils are dilated.1 The 
images created give the average RNFL thickness in micrometres. Another image of the 
retinal displays a colour-coded map of the retinal fibre layers (Figure 1).19 Unlike the 
healthy retinal fibre layers shown in Figure 1, a glaucomatous OCT will display a 
cupping form within the layers. The OCT can provide measurements of the cup area, 
disc area, and cup-to-disc ratio. Comparative images of the left and right eye are 
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created to compare the RNFL of both eyes and to analyse the symmetry between eyes. 
Asymmetry between the eye can be a sign of glaucomatous loss.20     
2.1.5 Glaucoma Screening 
Screening and diagnostic tools are significant to prevent glaucoma from 
progressing to advanced stages and maintaining healthy vision.21 In addition, glaucoma 
prevention will minimize future healthcare costs. The total cost of glaucoma treatment is 
estimated to be $1480 for mild, $3682 for moderate, and $4975 for severe forms of 
glaucoma.22 Screening can improve the efficiency of the health care system by 
increasing the number of patients accessing ophthalmic services and reducing the 
number of false-positive referrals to ophthalmologists.23 
The standard of care for glaucoma screening consist of routine optometrist visits 
every 2-3 years and any glaucoma suspect patient will be referred to an ophthalmologist 
for additional diagnostic testing.24 Those of older ages are at a greater risk of glaucoma 
and thus ophthalmologists recommend routine optometrist visits every 2 to 4 years for 
adults between 40 to 64 years and every 1 to 2 years when aged 65 and older.21 
Patients regularly seen by an ophthalmologist for other ocular conditions may also be 
referred for glaucoma diagnostic testing if symptoms appear. In-patient examination will 
be referred to as “in-person” examination. In-person examination for glaucoma (passive 
“in-person screening”) is performed at specialized clinics and includes detailed history, 
slit lamp examination, visual field testing, and fundus photography performed by the 
optical technician followed by consultation with the ophthalmologist.25,26 This is 
considered no-screening or the “do-nothing” approach where glaucoma suspects go to 
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in-person care when symptomatic. The “do-nothing” refers to that fact that the 
healthcare providers are not actively searching for potential candidates to screen. 
Patients go to visit the optometrist or ophthalmologist when they feel necessary. In 
contrast, “active screening” refers to teleglaucoma screening where healthcare 
providers actively seek people at-risk of glaucoma within the general population and 
these people are encouraged to be screened.  
2.1.6 Teleglaucoma Screening 
Teleglaucoma is a relatively new screening and diagnostic tool for targeting 
remote or under-serviced communities. It uses stereoscopic digital imaging to take 
ocular images, which are transmitted electronically to an ocular specialist. The ocular 
specialist will then assess the images, identify risk factors, and diagnose for glaucoma. 
If necessary, the ocular specialist will refer identified glaucoma cases for medical 
consultations or to ophthalmologists for follow-up treatment. Unlike other 
teleophthalmology tools, teleglaucoma requires more sophisticated diagnostic tests. 
The main tests are optic nerve photographs, Optical Coherence Tomography (OCT), 
Intraocular Pressure (IOP) measurements, central corneal thickness (CCT) 
measurements, and visual field tests.27-29 The combination of examinations and 
equipment required can vary based on organizational resources, target goals, and 
populations. However, the more diagnostic tools used during screening for glaucoma 
the greater the accuracy and effectiveness of the screening process. The equipment 
required for teleglaucoma are the ophthalmic examination equipment, cameras, and 
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computer imaging software. The full list of the standard equipment and components of 
teleglaucoma can be found in Table 1.27-29  
Several studies have reported on the effectiveness of teleglaucoma. 
Teleglaucoma technology demonstrated moderate agreement in its ability to diagnose 
glaucoma (Kappa statistic 0.55% [0.48, 0.62]).30 When disc damage had Vertical Cup to 
Disc Ratio (VCDR) greater than 0.7 the Frequency Doubling Technology  (FDT) had a 
substantial agreement with the ability to diagnose glaucoma (kappa statistic 0.84).30 In 
addition, a study conducted in rural India compared the ability of teleglaucoma to detect 
glaucoma compared to standard in-clinic examination and found that there was a good 
agreement in detecting glaucoma. For glaucoma the kappa scores were 0.61 with 
standard screening versus 0.59 for teleglaucoma.31 In comparison to the in-person slit 
lamp examination, the positive predictive value was 77.5% for positive teleglaucoma 
diagnosis and it had a negative predictive value of 82.2% for negative teleglaucoma 
diagnosis.30 This suggests that the probability of a positive test in a glaucoma positive 
case is 77.5%. Also, the probability of a negative test in a glaucoma negative case is 
82.2%. However, a cohort study conducted by the University of Alberta found 24% of 
teleglaucoma photographs were deemed unreadable from media opacities, patient 
cooperation, and unsatisfactory photographic techniques.30  
The advantages of teleglaucoma include convenience, decreased travel time to 
medical clinics, increased access to specialized care for glaucoma, and decreased 
patient costs. The benefits are mainly seen in remote or under-serviced communities 
such as Aboriginal communities, rural Manitoba, as well as Alberta where there is 
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limited ocular specialists. Teleglaucoma wait time reduction was 41% versus 19% with 
in-person examinations.32 Arora et al. reported improved access time (time from patient 
being referred to the date visit is booked) of 45 days with teleglaucoma versus 88 days 
for standard in-person examinations.38 Teleglaucoma had reduced cycle time (time from 
registration until patient leaves clinic) of 78 minutes versus in-person exam of 115 
minutes.32 The pioneer teleglaucoma study conducted in Finland reported reduced 
absence from work by 50% with teleglaucoma versus in-person examination, and in 
addition reduced traveling (97%), costs (92%), and time (92%).33   
2.1.7 Systematic Review  
The purpose of systematic reviews (SR) is to synthesize research literature from 
published and unpublished sources about a research topic.34 There are several steps in 
the process of conducting a systematic review.34,35 First is to define the question. It is 
important to specify the inclusion and exclusion criteria, the population, the intervention, 
the outcome, and methodology. The second step is to conduct the literature search. 
This involves choosing information sources both published and unpublished sources 
and identifying titles and abstracts. Once the articles are generated and organized into 
the database the articles are then screened using the inclusion and exclusion criteria. 
Level 1 screening is applied to titles and abstracts. Level 2 screening involves obtaining 
full text articles for eligible studies and applying the inclusion and exclusion criteria. Two 
reviewers conduct the screening. At each stage, the reviewers compare agreements 
and disagreements to ensure article eligibility. If disagreements occur, then a third 
reviewer intervenes and makes the decision. The fourth step is to create a database 
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with important study variables. The data extraction is then conducted and information is 
collected on each study’s population, interventions, comparison, and study design. In 
addition, other study variables include the results, methodologic quality, and validity 
agreement. The last step is to conduct the analysis and generate pooled estimates. It is 
important to assess variability amongst studies, which is the level of heterogeneity. 
Publication bias, a common bias affecting systematic reviews, is the selective 
publication of studies. Publication bias is tested using funnel plots.  
Systematic reviews are useful for determining if study results are valid. It 
analyzes the methodologic quality of studies and it examines the reproducibility of 
studies. It summarizes the results and determines if there is variability in study results. It 
also gives the precision of results.35 The significance of systematic reviews is that it 
gives the summary of all research literature in one document. This makes it easy for 
clinicians, policy makers, and healthcare care administrators to be informed of the 
evidence. It provides pooled estimates necessary for decision makers to make 
evidence-based decisions. Systematic reviews are useful for determining important 
patient outcomes and furthermore, how to apply the results to patient care.     
2.1.8 Meta-analysis 
Meta-analysis are a continuation of systematic reviews that add precision to the 
synthesized results. They are a formal, quantitative study to assess the strength of 
existing evidence on the specific research question. The meta-analysis is beneficial to 
determine if a treatment effect exists, if the effect size is positive or negative, and the 
relative treatment effect in comparison to the comparator.36     
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The statistical analysis involves the calculations of effects sizes in forms of risk 
ratios, odds ratios, and standardized mean differences depending on the exact study 
purpose. Studies are weighted for analysis based on the value of the evidence in each 
study and its sample size. More specifically studies are weighted according to the 
inverse of their variance.36 Thus, studies with smaller sample sizes will contribute less to 
the pooled estimate of effect size. There are two main models used in meta-analysis 
when generating the effect sizes: fixed effects and random-effects models.36 In the 
fixed-effects model, the source of variation in study results occurs from within each 
study. This model is homogenous, which means that the study treatments, populations, 
and other study variables are the same amongst studies. In contrast, the random-effects 
model assumes there is heterogeneity among study results. Studies are weighted by 
the inverse of their variance and the heterogeneity parameter.  
Hierarchical logistic regression model is another model that incorporates aspects 
of both fixed-effect and random-effect models.37 It is used for mixed models that have a 
group structure.38 The theory of hierarchical modelling is that at the micro level the 
normal logistic regression is used, but the coefficients may vary for each macro level 
observation. At the macro level, the micro level coefficients are functions of the macro 
level regression.39 Hierarchical models are useful for multilevel analysis where there is 
within study variance, as well as, between study variance.39 This is because hierarchical 
models are good for modelling specificity and sensitivity. This model is also useful for 
measures with binary responses. In addition, it is useful for meta-analyses as it takes 
into consideration the effects of study-specific covariates.  
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From the hierarchical regression modeling a Hierarchical Summary Receiver 
Operating Curve (HSROC) is generated, which provides the accuracy of the screening 
tool. It graphs both sensitivity and specificity to give a pooled estimate from all of the 
reported study estimates. The pooled estimate lies within a line or curve called the 
“summary line”.40 Summary lineis used when there are no covariates and  is calculated 
using parameters from the bivariate model. The summary line shows the range of the 
pooled estimates of sensitivity and specificity separately, and it represents the 
relationship between specificity and sensitivity.40 Therefore, it demonstrates how 
changing the summary specificity affects the summary sensitivity.  
Both the summary estimate and the summary line are interpreted against the 
clinical threshold to determine if the screening tool is accurate or not. Firstly, the 
curvature of the line is important; if there is a positive upward slope, this shows there is 
a positive relationship between specificity and sensitivity.40 Secondly, the area under the 
curve represents the accuracy. The greater the area under the curve the higher the 
accuracy. Generally, if the HSROC lies above the threshold line, which lies at a 45 
degree angle, then the accuracy is better than random chance.40 Also, if the HSROC 
lies above the clinical threshold stipulated by physicians or health experts then that 
screening tool is deemed clinically acceptable.40           
The HSROC curve also provides the 95% confidence region which is the 
confidence interval of the summary estimate. The confidence region is the range of 
estimates that are likely to include the true estimate with 95% probability.41 HSROC also 
gives the 95% prediction region, which is the region that the future observation will fall 
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given the existing data with 95% probability.41 Both measures are useful for researchers 
and clinicians to understand the distribution of the data, and the predicted data. It also 
gives the statistical significance of the summary estimate. The wider the confidence or 
prediction regions, the less statistically significant the summary estimates.   
One of the benefits of meta-analysis is it assesses the sources of heterogeneity 
among studies.35 Note, one of the purposes of meta-analyses is to determine which 
treatment/intervention is more effective. Thus, identifying the sources of heterogeneity 
can assist in interpreting the results and generating the conclusions of the meta-
analysis. Study results should be interpreted with caution when heterogeneity, the 
variation among studies, exists.36 This may call for subgroup analysis to determine the 
factors or covariates affecting the study results.  
There are two kinds of variability in studies: clinical diversity and methodological 
diversity.36 Clinical diversity is the variability in the study’s population, intervention, 
and/or measures. Whereas, methodological diversity is the variability in the study 
design and its related risks of bias. 
Heterogeneity is quantified using the inconsistency index I2. The I2 is given by a 
percentage of total variation across studies and ranges from 0 to 100%.35,36 If I2 is 
greater than 75% then there is substantial heterogeneity amongst studies.35,36  
Both systematic reviews and meta-analysis have been used extensively in 
ophthalmology to synthesize ophthalmic literature on glaucoma, diabetic retinopathy, 
cataracts, and all other eye diseases. They have been applied to determine the 
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effectiveness of many interventions including the effectiveness of screening strategies. 
The Cochrane Review has published a systematic review on the effectiveness of 
screening for glaucoma and found that screening is effective in glaucoma populations 
specifically when targeting at-risk population.21 
Several systematic reviews and meta-analysis have been conducted on 
teleophthalmology use for diabetic retinopathy, however, no studies have looked at the 
literature on teleglaucoma as discussed earlier. 
2.1.9 Specificity and Sensitivity 
 The two main measures of screening effectiveness are specificity and sensitivity. 
Both are independent of the population or prevalence. Specificity is the ability of the test 
to correctly detect the people who do not have the disease.40 Statistically it is calculated 
by the number of negative tests divided by those without the disease.42 The 
denominator are those without the disease which include both the true negatives cases 
who test negative (true negatives) and the negative cases who test positive (false 
positives). 
 Sensitivity is the ability of the test to correctly detect positive cases in those with 
the disease.40 The higher the sensitivity the more effective the test is at detecting 
positive cases. Statistically, it is calculated by the number of true positives tests divided 
by the number of people with the disease.42 Likewise, the denominator are those with 
the disease which include both the true positive cases who test positive (true positive) 
and the true positive cases who test negative (false negatives). 
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 For teleglaucoma, both the sensitivity and specificity are important; it is good 
practice to detect both the negative and positive cases correctly for efficient patient care 
and patient health outcomes. However, the sensitivity of teleglaucoma is particularly 
important because it incorporates the false negatives.42 The false negatives are the 
patients who have the disease and are incorrectly detected as a negative test. This 
patient group will be told they do not have the disease and continue living as normal. 
However, with glaucoma, this is particularly crucial to avoid. Glaucoma is a silent thief of 
vision and if left untreated patient can lose substantial visual acuity as well as suffer 
from visual defects. Thus, the sensitivity of teleglaucoma is important to prevent 
glaucoma cases from leaving the clinic without appropriate medical care.           
 
2.1.0 Cost-Effectiveness Analysis 
Economic evaluations are an essential part of healthcare. Specifically, cost-
effectiveness analysis (CEA) is an economic evaluation used by policy makers and 
healthcare administers to make decisions in healthcare.43 Directions in health care, as 
well as other areas of the public sectors, are based primarily on funding and the 
expected benefits.43,44 Hence, CEA describes the relationship between the costs and 
the effects (expected benefits) of interventions. CEA provides the evidence of where 
healthcare funds should be applied. Thus, the significance of CEA is that, it determines 
resource allocation and which health programs/interventions are funded.  
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In terms of ophthalmology, CEA is useful for comparing the costs and effects of 
different treatments for glaucoma, diabetic retinopathy, cataracts, etc. This economic 
evaluation can help determine which intervention is  cost-effective and should be 
implemented. In addition, the beauty of CEA is that it can use quality of life measures as 
the effect data, such as quality-adjusted life years (QALY) or utility values.43 Thus, an 
intervention in glaucoma that increases the visual field by 15% which is equivalent to 
improvement of 0.12 QALYs, is equivalent to a cardiac intervention that reduces blood 
flow by 0.02%, which is also equivalent to a 0.12 QALY improvement. This allows 
comparison of ophthalmic interventions to non-ophthalmic interventions. Thus, CEA 
provides healthcare administrators and policy makers’ essential tools to allocate 
resources among different health care areas.43 CEAs can generate conclusions on the 
benefits to the health care system and improvements in health service quality. More 
specifically, glaucoma is a chronic and progressive disease. As discussed earlier, there 
is no cure for glaucoma, hence the cumulative cost of living with the disease increases 
as patients live longer with the disease and increase substantially as the patients 
progress to advanced stages. CEA can be beneficial at assessing the long term costs 
and benefits associated with glaucoma.44 It is important to know the long term benefits 
after interventions for glaucoma are implemented. Also, CEAs can provide the long term 
patient health outcomes and its associated costs, which is essential to health care 
planning.      
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2.1.11 Conclusion 
Overall, teleglaucoma has potential to increase the access to ophthalmic care in 
rural and under-serviced areas where there is either limited ophthalmologists or 
requirement of a long travel. It is predicted that with teleglaucoma, there will be 
increased quality of life in patients with glaucoma. With progressive permanent vision 
loss as the main factor affecting a patient’s quality of life, detecting glaucoma patients 
through screening can assist to prevent vision impairment.  
 
2.2 Thesis Rationale 
 Current health reforms are shifting towards “e-health;” the incorporation of 
technology within healthcare to bring together distant communities and to improve 
access to expert medical advice and diagnosis.45,46 Telemedicine facilitates 
communications across geographic borders and across interdisciplinary networks. In 
many areas of health care, telemedicine has allowed more informed decision making 
and improved quality of care.45-48 It is efficient and convenient and it has benefits to 
improving the efficiency of administration.47,48 Telemedicine has demonstrated cost-
effectiveness in delivery of care for other health diseases.45,46 Specifically, rural and 
elderly populations both benefit from remote in-home consultation.47,48    
The use of telemedicine in ophthalmology (tele-ophthalmology) is not a new 
concept. Several studies have examined the use of tele-ophthalmology for screening of 
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diabetic retinopathy and found tele-ophthalmology played an effective role in screening 
diabetic retinopathy.49-542-57 However, few studies have examined the use of tele-
ophthalmology for glaucoma screening, in terms of its sensitivity, specificity, and time-
savings.  
Tele-ophthalmology is an emerging screening technique that can be effective for 
glaucoma detection for several reasons. Firstly, glaucoma is an age-related disease 
affecting the elderly populations. Teleglaucoma allows remote consultations which 
reduces travel time, and thus, the elderly population may benefit from the convenience 
of teleglaucoma.45,48,49 It promotes senior wellness and improved quality of life for the 
elderly. Secondly, glaucoma causes peripheral vision loss initially as opposed to 
diminishing visual acuity. As a result, patients may not notice visual field defects initially. 
It has been reported that 50% of cases are not detected until the advanced stages of 
the disease.2 Introduction of teleglaucoma can detect cases that may not have been 
detected otherwise.28 It is hypothesized that screening of elderly populations and 
populations at-risk will detect potential cases and cases at earlier stages of the disease. 
In addition, vision loss and visual defects due to glaucoma are permanent. 
Teleophthalmology would be beneficial to glaucoma patients as it can capture cases 
earlier thereby avoiding vision loss and permanent blindness. In return, preserving 
vision through teleglaucoma will improve the quality of life of patients. Therefore, the 
thesis rationale is that tele-ophthalmology may have a significant contribution for 
glaucoma management and have a significant impact on glaucoma patients.  
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Research has been conducted on the effectiveness of teleglaucoma and the 
direct benefits to patients and the healthcare system. However, to date, there is no 
synthesis of the research data. Synthesized effectiveness data is required to make 
informed decisions and to implement this technology for glaucoma screening. 
Healthcare decisions are based on research evidence. In addition, there are cost 
implications for implementing teleglaucoma. Research on the cost-effectiveness of 
teleglaucoma has not been published in research literature. This thesis will contribute to 
research literature by synthesizing the data on the effectiveness of teleglaucoma and 
analyzing the cost-effectiveness of teleglaucoma.    
 
2.3 Thesis Objectives 
 There are two objectives of this thesis. The first objective is to determine the 
effectiveness of teleglaucoma in-comparison to standard in-person examination for 
glaucoma screening. This thesis will synthesize information on diagnostic accuracy, 
benefits to health care service quality, and improvements to patient quality of life. The 
second objective is to determine the cost-effectiveness of teleglaucoma in rural areas 
for at-risk populations. 
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2.5 Tables 
Table 2.1 Standard teleglaucoma equipment 
Components Requirements 
Human Resources Staff: graders, Ophthalmic technicians, nurses, 
optometrist, physicians, glaucoma 
specialists/ophthalmologists 
Information Technology Secure Diagnostic Imaging (SDI) system 
 Videoconferencing equipment 
 Computer systems and software 
 ISDN installation 
Screening Equipment Retinal camera 
 Tonometer 
 Devices to measure central corneal thickness 
 Frequency Doubling Technology (FDT) or Humphrey 
Visual Field test 
 Optical Coherence Tomography 
 Slit lamp 
 Gonioscope  
Examinations Medical & family history 
 Visual acuity 
 IOP 
 CCT 
 Pupil equal  and reactive to light (PERL) or relative afferent 
pupillary defect (RAPD) 
 Slit lamp 
 Gonioscopy 
 Visual field 
 Fundus photographs 
 OCT 
 Ancillary tests 
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2.6 Figures 
Figure 2.1: OCT Image of a healthy retina19  
 
Footnote: Morrison, J. C., & Pollack, I. P. (2003). Glaucoma: Science and practice. New York: Thieme 
Medical Publishers. 
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CHAPTER 3 The effectiveness of teleglaucoma versus in-person 
examination (Systematic Review and Meta-Analysis) 
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3.1 Introduction 
Glaucoma is the leading cause of irreversible visual impairment in the world 
affecting 60.5 million people worldwide in 2010, which is expected to increase to 
approximately 79.6 million by 2020.1 Therefore, glaucoma screening is important to 
detect, diagnose, and treat patients at the earlier stages to prevent disease progression 
and vision loss. Teleglaucoma uses stereoscopic digital imaging to take ocular images, 
which are transmitted electronically to an ocular specialist. Teleglaucoma involves 
standardized equipment (Table 1). The purpose is to synthesize literature to evaluate 
teleglaucoma, its diagnostic accuracy, healthcare system benefits, and cost-
effectiveness. This chapter has been recently published.2 
3.2 Methods 
3.2.1 Search Strategy 
 A search methodology was used to assist in locating both published and 
unpublished studies. Research databases and conference meeting abstracts were 
searched for articles published from 1999 to current, and included MEDLINE (OVID and 
PubMed), Cochrane Library (Wiley), BIOSIS (Thomson-Reuters), CINAHL (EBSCO), 
Web of Science (Thomson-Reuters), and EMBASE (OVID). The grey literature was 
explored by searching Dissertations and Theses (ProQuest), the Canadian Health 
Research Collection (Ebrary), as well as the annual meeting abstracts of the European 
Society of Ophthalmology, Canadian Ophthalmology Society (COS), Association for 
Research in Vision and Ophthalmology (ARVO), and American Academy of 
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Ophthalmology (AAO). The Conference Proceedings Citation Index was also included 
as part of the Web of Science search. Hand searches of ARVO’s Investigative 
Ophthalmology & Visual Science journal and Canadian Journal of Ophthalmology 
associated with COS were performed. The search strategies employed database 
specific subject headings and keywords for glaucoma, tele-screening, detection, and 
their synonyms. Each strategy was structured to accommodate for database and 
platform specific terminology, and syntax. The appendix contains the complete search 
strategies used for the various databases (Appendix 2). Alerts were set up for each 
database to receive publication notifications for new related articles. 
3.2.2 Inclusion and exclusion criteria 
 Articles included were from any country, all in English, published from 1999 to 
current, and were research articles. The articles included a study population that 
consisted of adults in the general population or populations at risk of glaucoma. The 
study population included those with or without glaucoma. Articles on teleglaucoma 
intervention for glaucoma screening were included, both in-comparison to in-person 
screening and analyzing teleglaucoma on its own. Outcome measures of teleglaucoma 
articles selected contained efficiency measures, specificity, sensitivity, and its ability to 
detect glaucoma, as well as patient benefits and cost data. Economic evaluations such 
as cost-effectiveness analysis and studies with costing data were also included.    
 Specificity of teleglaucoma for this study was defined as the proportion of non-
glaucoma cases who were correctly detected by teleglaucoma as a negative screen 
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test.3 Whereas, sensitivity of teleglaucoma was defined as the proportion of glaucoma 
cases who were correctly detected by teleglaucoma as a positive screen test.3 The 
proportion of true positive and negative cases are given through the diagnostic tests 
conducted by the ophthalmologist. Patients who were diagnosed by the 
ophthalmologists as glaucoma-positive were considered “true positives” and the 
patients who were diagnosed by the ophthalmologist as non-glaucoma cases were 
considered “true-negatives”.      
The exclusion criteria consisted of articles published prior to 1999 since 
teleglaucoma is fairly new and to be consistent with the teleglaucoma screening 
procedure, year 1999 was selected as a cut-off year. Additionally, non-research articles 
such as methodology papers, editorials, review articles, commentaries, and letters were 
excluded. Articles on diagnosis or prognosis, genetic screening, and teleophthalmology 
for ocular conditions other than glaucoma were eliminated.    
A total of 11,237 articles were retrieved by searching various databases and an 
additional 526 were retrieved from hand searching and grey literature search, which 
were then imported into EPPI 4.0 reference manager. Based on the inclusion and 
exclusion criteria, two reviewers independently reviewed all articles. After removing 
duplicate articles, 8157 articles were included for screening. Articles were screened by 
title, abstract, and full text in level 1, 2, and 3 screening, respectively. After each level of 
screening, kappa statistics was calculated to measure reviewer’s agreement. 
Additionally, if consensus was not reached by the two reviewers;’ then a third reviewer 
intervened to solve disagreements on article eligibility. The agreement between the two 
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reviewers was excellent (kappa = 0.86). The PRISMA diagram demonstrating the 
selection process is displayed in Figure 1. 
3.2.3 Quality Assessment Strategy 
 Articles were assessed using the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) guidelines for publication bias, risk of bias, 
imprecision, inconsistency, and indirectness.4-9 Articles were graded as either low, 
moderate, or high quality of evidence. The results indicated that 17 articles were high 
quality, 13 were moderate quality, and 15 articles were graded as low quality of 
evidence. Despite the quality of evidence, all articles were included in the analysis.    
3.2.4 Data Extraction Strategy  
 Qualitative and quantitative data necessary for the analysis was obtained from 
each article. Information on study location, design, effect measures (sensitivity and 
specificity), percentage of glaucoma diagnosed, service times, image quality, visual 
acuities, ophthalmic characteristics, and costs were collected. One reviewer extracted 
data using an excel template. Authors were emailed to obtain missing relevant 
information. All databases were updated with new information from respective authors. 
Additional current costing data was provided by ophthalmic equipment vendors, 
INNOVA, Topcon, and Ocular Health Network. Costs were converted to 2014 US 
dollars.10-14 This research study has no financial relationships, investments, or 
sponsorship related to the cited commercial vendors. 
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3.2.5 Data Analysis 
 Data was synthesized and analyzed using STATA 13. When studies reported 
estimates as a range or p-value or multiple estimates, mean and standard deviation 
(SD) were derived. Hierarchical logistic regression was used to determine the pooled 
estimates of sensitivity and specificity of teleglaucoma, and in-person examination. 
Hierarchical modeling was used because it is appropriate for mixed models with group-
level data.15 It incorporates both fixed-effects and random-effects models.16 The dataset 
of this study consists of both within study variance and between study variance. Thus, 
hierarchical logistic regression modelling would allow multilevel analysis.15,16 A graphical 
representation of the summary estimates was presented in a Hierarchical Summary 
Receiver Operator Characteristic (HSROC) curve with 95% confidence intervals and 
95% prediction regions.  
The positive/negative likelihood ratios (LR+/LR-) were calculated using bivariate 
models to generate estimates of the likelihood of a positive/negative test in a 
glaucoma/non-glaucoma patient. From this result the diagnostic odds ratio (DOR) was 
calculated to determine the relative diagnostic effectiveness of teleglaucoma. DOR is 
the ratio of the odds of a positive screen test in a glaucoma case relative to the odds of 
a negative screen test in a non-glaucoma case.17  
Due to the variability of study effectiveness measures, not one article had a 
complete set of data. Missing data were missing completely at random.18 The data was 
missing due to many reasons such as findings were not reported or the study objectives 
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were different.  Missing data were treated as statistically missing and was coded in the 
dataset accordingly. This means that the missing values did not contribute to any 
denominator counts or sample size counts. As a result, the missing data was not 
included in the analysis. Only articles with complete data were included in each 
analysis. Study heterogeneity was assessed statistically with the calculation of the I-
square.  
3.3 Results 
A total of 45 studies (101,512 participants) were included in this meta-analysis. 
Table 3.2 and Table 3.3 display the baseline characteristics of each study. Studies were 
conducted in 14 different countries with representation in each continent. All articles 
were published between 1999 and 2014. All studies were observational studies, as 
there were no randomized controlled trials conducted. Three studies contained 
economic evaluations or cost-effectiveness analysis. Of the 45 studies, 16 compared 
teleglaucoma to in-person examination. The other 29 studies analyzed teleglaucoma 
without comparison or used an evaluation of different teleglaucoma equipment. There 
was minimal variation in study populations; they included either glaucoma patients or 
patients who were at risk of glaucoma (based on diabetes status, family history of 
glaucoma, age, or ethnicity). Table 4 displays additional study details on demographics 
and study methods (glaucoma definition, pupil dilation, and number of field tests 
examined). Although there was some variation, less than 10% of studies reported these 
details. The main outcome measures were specificity and sensitivity (Table 3.5). Other 
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included outcome measures displayed in table 3.5 are: percentage of glaucoma 
diagnosed, referral rate, and proportion of images with poor quality.    
Costing data was given by nine studies and the quality of analysis of costing is 
displayed in table 3.6. Teleglaucoma costs vary by the capacity of the service and the 
type and amount of equipment. The current vendor estimate shows that the total costs 
for standard glaucoma equipment range from 89,703.53 to 123,164.55 US dollars 
(Table 3.6).11,12 Additionally, to transfer images and patient test results securely to 
ophthalmologists electronically, a service exists costing $62.13 US/month.10,13 This 
service allows teleglaucoma technicians and ophthalmologists to log-in electronically to 
attach, send, view, and assess retinal images and patient test results.  
There was a wide range of costing data reported in literature. To demonstrate the 
distribution, the costing data from the literature shows the cost per detected case of 
glaucoma ranged from $13.03 – 2020.96 US after conversion to US dollars and 
adjusted for inflation to 2014 costs (Table 3.7).13 The range represents teleglaucoma 
with minimal to optimal amount of resources. The lower range is represented by smaller 
teleglaucoma services with one grader and one diagnostic instrument (tonometer). The 
higher range represents a larger teleglaucoma service with a few graders, technicians, 
and nurses, and the full set of ophthalmic instruments outlined in Table 3.1.The mean 
cost is $1098.67 US for every case of glaucoma detected (n=3) (Table 3.7). The mean 
cost of teleglaucoma per patient screened was $922.77 US (n=2) (Table 3.7).  
44 
 
 
 
Another necessary costing aspect is the ophthalmologist fee for glaucoma 
consultation. The ophthalmologist may be compensated for each teleglaucoma referral 
or time spent on teleophthalmology consultations. Compensation varies by states 
and/or provinces, government legislation, and available private grants. In the United 
States, Medicare and Medicaid provide several reimbursement programs for physicians 
delivering telemedicine consultations.18,19 In Ontario, Canada, the compensation for the 
fee-for service model, is $16.00 CAN per ophthalmic referral.20 The physician liable for 
teleglaucoma consultations must be a licensed ophthalmologist in both the area of the 
service and the patient. Physicians must hold liability coverage appropriate to 
state/provincial laws. In Canada, the Canadian Medical Protective Association provides 
ophthalmologists with liability coverage for teleophthalmology.21 
  Ten studies had complete data to be included for the analysis for teleglaucoma 
diagnostic accuracy. The summary estimate for sensitivity was 0.833 [95% CI 0.77, 
0.88] and specificity was 0.79 [95% CI 0.668, 0.875] for glaucoma screening using optic 
nerve examinations (Appendix 3). The summary estimates indicate that teleglaucoma 
correctly detects 83.3% of glaucoma cases and correctly classifies 79% of those without 
glaucoma as glaucoma-negative. Figure 3 displays each study estimate and the 
summary estimate with its associated confidence intervals and the generated HSROC 
curve. The HSROC curve demonstrated a fairly narrow range which indicates that 
changing the summary specificity moderately affects the summary sensitivity. The 
HSROC curve was a positive upward slope indicating a positive relationship between 
specificity and sensitivity; there is a positive trade-off between the two effectiveness 
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measures. The HSROC curve lies above the threshold, indicating the accuracy of 
teleglaucoma is better than random chance. The HSROC curve appears in the left 
upper quadrant and provides a large area under the curve. This is an important 
measure of accuracy; because the area under the HSROC curve is large, this means 
teleglaucoma is a relatively accurate screening device.    
The distribution of the studies in the HSROC plot demonstrates the variability of 
both specificity and sensitivity amongst studies. Six studies fall outside of the 95% 
confidence interval of the summary estimate. The 95% prediction region is the estimate 
of future observations. The results demonstrate a fairly wide prediction region for both 
true predictions of specificity and sensitivity, with greater variability expected for 
specificity.  
The study populations used to assess diagnostic accuracy were those at-risk of 
glaucoma (based on diabetes status, family history, age, ethnicity, etc.), optometrist and 
ophthalmic clinic patients, and patients who were glaucoma suspects (Table 3.1). One 
study reported its study population as glaucoma patients only (Table 3.1) and on the 
contrary, this study had one of the lower reported scores for diagnostic accuracy: 
specificity was 71.5% and sensitivity was 67% (Table 3.5).24   
The diagnostic tools of the included studies varied slightly (Table 3.8). Eight out 
of the ten studies analyzed for sensitivity and specificity used at minimum optic nerve 
examinations as part of the screening process (Table 3.8). The other two studies 
reported using IOP or visual field defects as the methods to detect glaucoma suspects 
46 
 
 
 
(Table 3.8). For these studies which did not include fundus photographs, the sensitivity 
and specificity were 81.5% and 95.5% respectively for glaucoma screening using only 
visual field and 38.1% and 98.8% respectively for glaucoma screening using IOP and 
Orbscan Topography (Table 3.5).25,26    
Three studies reported sensitivity and specificity of in-person examination. The 
weighted mean of sensitivity was 74.9 + 27.6% (n=3) and specificity was 88.8 + 10.3% 
(n=3) for in-person examination. The summary estimates indicate that in-person 
examination correctly detects 74.9% of glaucoma cases and correctly classifies 88.8% 
of those without glaucoma as glaucoma-negative.  
The positive likelihood ratio was 3.97 [95% CI: 2.3-6.7] while the negative 
likelihood ratio was 0.21 [95% CI: 0.14-0.32] (Appendix 3). This demonstrates that the 
likelihood of a positive screen test in a glaucoma case is greater than the likelihood of a 
negative screen test in a non-glaucoma case.  In addition, the positive likelihood ratio is 
greater than one and thus the positive screen test is associated with glaucoma. Since 
the negative likelihood ratio is less than one, the negative screen test is associated with 
the absence of the disease.17 The effectiveness of the diagnostic accuracy of 
teleglaucoma was given by the DOR, which was 18.7 [95% CI: 7.9-44.4] (Appendix 3). 
The relative odds of a positive screen test in glaucoma cases are 18.7 times more likely 
than a negative screen test in a non-glaucoma case. Since the DOR was greater than 
one, the test is discriminating between true positives and true negatives correctly.17  
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There was insufficient data to conduct hierarchical logistic regression on the 
percentage of glaucoma diagnosed. Three of the 45 studies reported percentage of 
glaucoma diagnosed in both teleglaucoma and in-person examination necessary for 
analysis. The mean percentage of glaucoma diagnosed was 13.4% for teleglaucoma 
and 7.8% for in-person examination which suggests that teleglaucoma is capable of 
detecting more cases of glaucoma.  
  Other effectiveness measures of teleglaucoma were analyzed such as variables 
of healthcare service quality. The mean percentage of patients referred to a specialist 
for consultation was 12.5 + 7.8% (n=6). The mean percentage of images that were of 
poor quality was 10.4 + 6.7% (n=7). It took a mean time of 75.6 + 87.7 seconds (n=4) to 
process the teleglaucoma images. Timing associated with teleglaucoma service is 
another measure of quality. The mean time for screening was 8.8 + 5.1 minutes (n=3). 
The time reported for an ophthalmologist to make a diagnosis was 34 minutes (n=1). 
The mean reporting time was 7.6 + 2.6 minutes (n=6). Teleglaucoma gave a 
reduction for patient travel time of 61.23 hours (n=1). Teleglaucoma had a mean access 
time (time from patient being referred to the date visit is booked) of 59.7 + 9.9 minutes 
(n=4) in comparison to 73.7 + 29.8 minutes (n=4) for in-person examination. The mean 
cycle time (time from registration until patient leaves clinic) for teleglaucoma was 81.7 + 
6 minutes (n=2), which was less than that of in-person examination, 116 + 2.5 minutes 
(n=2). The mean proportion of patient satisfaction with teleglaucoma was 47.3 + 8.8% 
(n=2) while only 42% (n=1) were satisfied with in-person examination. 
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 The heterogeneity amongst the studies was given by the I-square. The I-square 
generated for specificity was 65.2% (p=0.05) and for sensitivity the I-square was 75.6% 
(p=0.52). This indicates there is moderate heterogeneity (50-75%) between studies 
regarding the specificity estimates.27 In addition, the I-square is statistically significant. 
Thus, the variation between studies is statistically significant. This can bias the pooled 
estimate for specificity. The I-square for sensitivity falls within the criteria for moderate 
and substantial heterogeneity (>75% indicates substantial heterogeneity).19,27 There 
was substantial variation between studies regarding the sensitivity estimate. However, 
the heterogeneity was not statistically significant (p>0.05). Thus, although there was 
heterogeneity reported, it was not statistically significant. Consequently, this means 
there was potential homogeneity rather than heterogeneity regarding the study 
estimates for sensitivity.19 Homogeneity, similarity between studies, is beneficial to the 
pooled estimate as it indicates a lack of bias.19               
3.4 Discussion 
Telemedicine has demonstrated good use for offering glaucoma services to 
people of remote areas. Teleglaucoma is beneficial to remote areas as the physician is 
not required to see patients in person, which reduces wait times and shortens the length 
of ophthalmic consultations. Teleglaucoma avoids long distance travel and time wasted 
on commute.  
The results of the pooled estimates for diagnostic accuracy have shown 
teleglaucoma to be less sensitive and more specific than in-person examinations. 
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Teleglaucoma is advantageous at detecting true positive cases of glaucoma, but has a 
higher rate of false positives in comparison to in-person examination. However, for 
teleglaucoma screening it is more important to have a low level of false negatives. This 
is because if cases of glaucoma are not detected, they are not treated. Without 
treatment, glaucoma can progress to advanced stages unknowingly. This is significant 
because as glaucoma progresses vision loss and visual defects become more severe 
and more importantly, visual impairment due to glaucoma is permanent. Thus, a low 
level of false negatives can avoid patients missing out on treatment. In addition, with 
very high DOR estimates, it is suggested that teleglaucoma can accurately discriminate 
screen tests.  
Teleglaucoma has demonstrated capability to detect glaucoma cases that may 
not have been detected during in-person examination. Glaucoma progresses without 
patient awareness and it is usually detected at the advanced stages. Thus, 
teleglaucoma serves as a tool for early detection of glaucoma. If caught earlier and with 
treatment, glaucoma can be effectively managed and can result in the preservation of 
vision.  
Telemedicine for glaucoma can have several combinations of examinations and 
measurements used for glaucoma screening. Examination of fundus photographs are 
commonly used for teleglaucoma screening. Four of the ten studies analyzed used only 
fundus examinations while another four studies included IOP, CCT, visual field loss, and 
visual acuity, in addition to fundus photograph examinations (Table 8). Two studies did 
not use fundus photograph examination, but rather visual acuity, IOP, CCT, and ACT 
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(Table 8). However, this is based on studies who explicitly stated the terms for 
ophthalmic examination. Some studies reported “comprehensive eye examinations” 
were performed, but did not explicitly state which examinations were performed, thus 
assumptions cannot be made. The use of different tests for glaucoma screening can 
potentially bias the results as the more diagnostic tools used during screening results in 
a greater probability of correct diagnosis naturally. However, the results did not show 
any significant differences in accuracy with studies which reported using multiple 
diagnostic tools. Interestingly, the specificity and sensitivity values reported ranged 
independent of the number and the type of examination used for teleglaucoma (Table 4 
and Table 8).   
The combinations of examinations are dependent on financial and resource 
limitations of the hosting organization and can vary from small programs to very large 
programs. It is dependent on the target goals and target populations of the organization. 
However, the standard examinations recommended for glaucoma screening are those 
that can evaluate visual field defects, IOP, and the biological structure and function of 
the optic nerve. These include HRT, OCT, optic disc photography, RNFL photography, 
as well as FDT, tonometry, and perimetry.27  
There were limitations within the study. Insufficient data reported was a major 
limitation of the meta-analysis, although authors were contacted for additional 
information. Nevertheless, the key goal was to systematically review the literature on 
tele-glaucoma and in-person screening and perform the meta-analysis. With small 
sample sizes there was not enough power to show statistical or clinical significance. 
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Different comparators were reported by studies and to ensure internal validity, only 
studies with exact comparators were analyzed together. This was one of the reasons for 
reduced sample sizes for the analysis.  However, our analysis does provide information 
on diagnostic accuracy of teleglaucoma, its capability to detect glaucoma, and to detect 
negative and positive cases correctly. It demonstrates teleglaucoma has the potential as 
a screening device to detect a greater amount of cases than in-person examination. 
Since teleglaucoma is an active screening, it suggests glaucoma cases are detected at 
earlier stages. However the significance of this difference is limited by the number of 
comparative studies. The majority of the studies were non-comparative which, in 
addition, limits the significance of the relative effectiveness to in-person examination. 
Teleglaucoma has been evaluated in many different ways: diagnostic accuracy, 
cost reduction, technological capabilities (image quality, image transmission speed, 
etc.), reduction of patient and health care provider time, and convenience. Thus many 
studies focus on part of the effectiveness. As a result, there is insufficient data when 
summarizing all of the studies together. This has proven the need for more research 
literature on the diagnostic accuracy of teleglaucoma and its ability to detect glaucoma 
in comparison to in-person examination. There is a need for research on the follow-up 
of detected cases and long-term effects of teleglaucoma. In addition, better quality of 
evidence through randomized controlled trials is recommended. There are implications 
for cost-effectiveness analyses. Although, costing data suggests cost savings for 
patients’ time and travel with teleglaucoma. Thus, a thorough costing of current health 
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care expenditure is required to determine its overall cost-effectiveness from the scope 
of the healthcare system.     
Teleglaucoma is beneficial to offering services in underserviced regions and rural 
areas. It considerably reduces patient access times and cycle times. The time required 
for service is shorter than in-person examination and physician commitments are 
reduced. As a result teleglaucoma saves costs to patients and costs to the health care 
system as a whole.   
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3.6 Tables 
Table 3.1: Standardized Teleglaucoma Equipment 
Components Requirements 
Human Resources Staff: graders, Ophthalmic technicians, nurses, optometrist, 
physicians, glaucoma specialists/ophthalmologists 
Information Technology Secure Diagnostic Imaging (SDI) system 
 Videoconferencing equipment 
 Computer systems and software 
 ISDN installation 
Screening Equipment Retinal camera 
 Tonometer 
 Devices to measure central corneal thickness 
 Frequency Doubling Technology (FDT) or Humphrey Visual 
Field test 
 Optical Coherence Tomography 
 Slit lamp 
 Gonioscope  
 Retinal camera 
 Tonometer 
 Devices to measure central corneal thickness 
Examinations Medical & family history 
 Visual acuity 
 IOP 
 CCT 
 Pupil equal  and reactive to light (PERL) or relative afferent 
pupillary defect (RAPD) 
 Slit lamp 
 Gonioscopy 
 Visual field 
 Fundus photographs 
 OCT 
59 
 
 
 
 Ancillary tests 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic Review and 
Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Table 3.2: Baseline Characteristics of Included Studies - Demographics 
Author (Year) Location 
Study 
Design 
Sample 
Size Population 
Tuulonen et al. 
(1999)23 Finland PC 70 Glaucoma patients 
Eikelboom et 
al. (1999)19 Australia PC 27 Glaucoma patients 
Li et al. 
(1999)24 USA PC 32 Diabetic adults 
Yogesan et al. 
(1999)25 Australia PC 27 
Glaucoma clinic 
patients/suspected of 
glaucoma 
Michelson et 
al. (2000)26 Germany PC 10 
Glaucoma-diagnosed 
patients 
Yogesan et al. 
(2000)27 Indonesia PC 14 Ophthalmic Clinic patients 
Yogesan et al. 
(2000)28 Australia PC 43 Ophthalmic Clinic patients 
Gonzalez et al. 
( 2001)29 Spain PC 139 Ophthalmic Clinic patients 
Sebastian et 
al. (2001)30 Spain CS 74 Glaucoma suspects 
Wegner et al. 
(2003)31 Germany PC 1733 Not stated 
Labiris et al. 
(2003)32 Greece PC 1205 
Glaucoma-diagnosed 
patients 
Fansi et al. 
(2003)33 Canada PC 33 
Glaucoma suspects or 
diagnosed 
Jin et al. 
(2003)34 Canada CEA 339 Diabetic aboriginals 
Chen et al. 
(2004)35  Taiwan PC 113 
Residents of area aged > 
40 years 
de Mul et al. 
(2004)36  Netherlands PC 1729 
Optometrist patients at-
risk for glaucoma 
Ianchulev et al. 
(2005)20 USA PC 33 
Glaucoma suspects or 
diagnosed 
Paul et al. 
(2006)37 India PC 348 
Rural residents at risk for 
glaucoma 
Kumar et al. 
(2006)21 Australia PC 107 Patients of the Eye Clinic 
Kumar et al. 
(2007)38 
New 
Zealand PC 201 
General eye examination 
clinic Patients  
Khouri et al. 
(2007)39 Not Stated CS 30 
Glaucoma-diagnosed 
patients 
Pasquale  et 
al. (2007)40 USA PC 350 Diabetic 
Khouri et al. 
(2008)41 USA PC 28 
Glaucoma-diagnosed 
patients 
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Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
 
 
 
 
deBont et al. 
(2008)42 USA PC 1729 
Optometrist patients at-
risk for glaucoma 
Sogbesan et 
al. (2010)43 Canada CEA/PC -- 
Optometrist patients at-
risk for glaucoma 
Anton-Lopez 
et al. (2011)44 Spain CS 1599 At-risk for glaucoma 
Khurana et al. 
(2011)45 India CS 91698 Ophthalmic Clinic patients 
Staffieri et al. 
(2011)46 Tasmania PC 133 
High risk (First degree 
relatives of diagnosed 
POAG) 
Swierk et al. 
(2011)47 Germany EE -- Ophthalmic Clinic patients 
Amin et al. 
(2012)48 Canada PC 72 
Glaucoma suspects or 
early stages of OAG 
Shahid et al. 
(2012)49 USA CS 341 
Urban soup 
kitchen/homeless 
Kassam et al. 
(2012)50 Canada PC 257 
At-risk for glaucoma or 
early-stage glaucoma 
Gupta et al. 
(2013)51 India PC 247 Ophthalmic Clinic patients 
Damji et al. 
(2013)52 Canada PC 71 Ophthalmic Clinic patients 
Kiage et al. 
(2013)53 rural Africa PC 309 Diabetic adults 
Verma et al. 
(2013)54 Canada RC 247 
Optometrist-referred 
glaucoma suspects or 
early OAG 
Ahmed et al. 
(2013)55 USA RC 643 Diabetic and hypertensive 
Arora et al. 
(2014)56 Alberta PC 71 
Glaucoma clinic 
patients/suspected of 
glaucoma 
Legend: CS = Cross-Sectional Study, PC = Prospective Cohort Study, CEA = Cost-
effectiveness Analysis, RCS = Retrospective Cohort Study, EE = Economic 
Evaluation, -- = Not Stated 
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Table 3.3: Baseline Characteristics of Included Studies - Intervention 
Author (Year) Teleglaucoma Equipment Comparator 
Tuulonen et al. 
(1999)23 
Canon CR5-45NM non-mydriatic fundus camera, slit-
lamp, Panasonic video camera, HF II perimeter 
In-person 
examination 
Eikelboom et al. 
(1999)19 Nidek Nm-100 Handheld fundus camera 
Teleglaucoma 
only 
Li et al. (1999)24 Non-mydriatic retinal camera. Digital images 
Image Quality 
of 
Teleglaucoma 
Yogesan et al. 
(1999)27 Portable fundus camera, Nidek NM100 
Teleglaucoma 
only 
Michelson et al. 
(2000)26 
Self-tonometry portable device called Ocuton, 
PalPilot, IOP curve 
Teleglaucoma 
only 
Yogesan et al. 
(2000)27 Handheld fundus camera (NM100) 
Teleglaucoma 
only 
Yogesan et al. 
(2000)28 
DIO digital indirect ophthalmoscope, handheld fundus 
camera Nidek NM100, stereo fundus camera ( Nidek 
3D-x) 
Teleglaucoma 
only 
Gonzalez et al.  ( 
2001)29 Non-mydriatic fundus camera (canon CR6-45M) 
In-person 
examination 
Sebastian et al. 
(2001)30 
C-20-5 FDT, Humphrey-Zeiss, & Topcon optic nerve 
head photographs 
Teleglaucoma 
only 
Wegner et al. 
(2003)31 Goldman applanation tonometer and mobile HRT 
Teleglaucoma 
only 
Labiris et al. 
(2003)32 
Slit lamp, Octapus perimeter visual field, fundus 
camera, Optotype, air tonometer 
In-person 
examination 
Fansi et al. 
(2003)33 -- 
Healthy vs 
Glaucoma 
eyes 
Jin et al. (2003)34 Tonometry  
In-person 
examination 
Chen et al. 
(2004)35 
Digital 35-degree colour fundus images, non-
mydriatic digital fundus camera (CR6-45, Canon) 
In-person 
examination 
de Mul et al. 
(2004)36 Nerve fibre analyser, GDx 
In-person 
examination 
Ianchulev et al. 
(2005)20 Peristat: self-test 
In-person 
examination 
Paul et al. (2006)37 
-- Teleglaucoma 
only 
Kumar et al. 
(2006)21  I-care tonometry 
Teleglaucoma 
only 
Kumar et al. 
(2007)38 -- 
In-person 
examination 
Khouri et al. 
(2007)39 Digital stereo fundus camera - Nidek 3-Dx 
Image Quality 
of 
Teleglaucoma 
Pasquale et al. Topcon TRC NW-5S non-mydriatic retinal camera Teleglaucoma 
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Author (Year) Teleglaucoma Equipment Comparator 
(2007)40 (Paramus) interfaced to a standard color video 
camera (Sony 970-MD) 
only 
Khouri et al. 
(2008)41 
Non-mydriatic 45-deg camera, Canon Japan. DICOM 
image format 
Image Quality 
of 
Teleglaucoma 
deBont et al. 
(2008)42 Nerve fibre analyser, GDx 
Image Quality 
of 
Teleglaucoma 
Sogbesan (2010)43 -- 
In-person 
examination 
Anton-Lopez et al. 
(2011)44 
HRT, nerve-fibre analyzer (GDX-VCC), I-Care 
(rebound tonometry) 
In-person 
examination 
Khurana et al. 
(2011)45 -- 
Teleglaucoma 
only 
Staffieri et al. 
(2011)46 
-- Teleglaucoma 
only 
Swierk et al. 
(2011)47 
-- In-person 
examination 
Amin et al. (2012)48 
Slit lamp, IOP, CCT, visual field, anterior and stereo 
posterior segment photos and OCT 
In-person 
examination 
Shahid et al. 
(2012)49 8.2 megapixel non-mydriatic retinal camera 
Teleglaucoma 
only 
Kassam et al. 
(2012)50 Remote service - slit lamp, fundus photographs,  
In-person 
examination 
Gupta et al. 
(2013)51 Fundus Camera (Portcam II) 
In-person 
examination 
Damji et al. 
(2013)52 -- 
In-person 
examination 
Kiage et al. 
(2013)53 Topcon 777 
In-person 
examination 
Verma et al. 
(2013)54 -- 
In-person 
examination 
Ahmed et al. 
(2013)55 Topcon TRC non-mydriatic retinal camera, Tonopen 
Teleglaucoma 
only 
Arora et al. 
(2014)56  -- 
In-person 
examination 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic Review and 
Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Table 3.4: Additional Details on Baseline Characteristics of Included Studies 
Author (Year) 
Study Population 
Ethnicity Glaucoma definition 
Dilated 
pupil 
# 
Field 
tests 
Eikelboom et al. 
(1999)
19 
– ‒ – ‒ 
Yes 
– ‒ 
Yogesan et al. 
(1999)
25 
– ‒ – ‒ 
Yes 
– ‒ 
Yogesan et al. 
(2000)
27 
– ‒ – ‒ 
Yes 
– ‒ 
Yogesan et al. 
(2000)
28 
– ‒ – ‒ 
Yes 
– ‒ 
Ianchulev et al. 
(2005)
20 
15% White, 9% 
African American, 
76% Hispanic 
– ‒ 
No 
– ‒ 
Chen et al.  
(2004)
35 
100% Asian "The diagnosis of glaucoma was made 
according to the anatomical findings 
from the patient’s optic nerve disc, and 
functional visual field examination by 
frequency-doubling perimetry (FDP). 
Intraocular pressure (IOP) was also 
evaluated. An elevated IOP was 
defined as over 17mmHg (1mmH = 133 
Pa). Severe glaucoma was defined as 
an optic cup: disc ratio over 0.7 with an 
FDP defect or elevated IOP. Mild 
glaucoma was defined as an optic cup: 
disc ratio between 0.7 and 0.5, or disc 
asymmetry of over 20%, with an FDP 
defect or elevated IOP." 
– ‒ – ‒ 
Kumar et al.  
(2006)
21 
96% Caucasian, 
4% Asian 
IOP of 21 mmHg was threshold for 
suspected glaucoma 
– ‒ – ‒ 
Paul et al.  
(2006)
37 
100% Indian – ‒ – ‒ – ‒ 
Kumar et al. – ‒ In accordance with glaucoma 
screening protocol of Lions Eye Yes 
– ‒ 
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Author (Year) 
Study Population 
Ethnicity Glaucoma definition 
Dilated 
pupil 
# 
Field 
tests 
(2007)
38 
Institute: Vertical cup disc ratio (VCDR) 
>0.5, IOP>21 mmHg, abnormal visual 
field related to glaucoma, and or disk 
asymmetry >0.2. 
Pasquale  et al. 
(2007)
40 
16% African 
American (of 
glaucoma 
suspects) 14% 
African American 
(Of non-glaucoma 
suspects) 
“VFs were considered glaucomatous if 
the pattern deviation plot showed a 
nasal step, nasal depression, arcuate 
defect, paracentral loss that respected 
the horizontal meridian, or temporal 
wedge defects based on previously 
published criteria... Patients were 
designated as “no glaucoma” if the 
CDR was "<0.6 in both eyes and CDR 
asymmetry was < 0.1 in the absence of 
reliable glaucomatous VFs. Patients 
were designated as having “glaucoma-
suspicious optic discs” if the CDR was 
"> 0.6 in either eye or CDR asymmetry 
was > 0.1 with or without reliable 
glaucomatous VFs. Patients with more 
subtle optic nerve changes were 
labeled as having glaucoma-suspicious 
optic discs if VFs were available and 
reliable and showed change consistent 
with glaucomatous loss." 
– ‒ 
Three 
Staffieri et al. 
(2011)
46 
– ‒ "Subjects were classified as having 
definite glaucoma on the basis of 
characteristic optic nerve head 
changes (cup: disc ratio [CDR] outside 
the 97.5 percentile for the normal 
population or rim width less than 0.1 
CDR at the superior and inferior poles 
of the disc) and definite visual field 
defect consistent with glaucoma. 
Individuals with stereoscopic disc 
photos consistent with structural 
damage but in whom field testing was 
unreliable or unobtainable were 
classified as glaucoma suspect." Yes 
– ‒ 
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Author (Year) 
Study Population 
Ethnicity Glaucoma definition 
Dilated 
pupil 
# 
Field 
tests 
Khurana et al. 
(2011)
45 
100% Indian – ‒ – ‒ – ‒ 
Anton-Lopez et 
al. (2011)
44 
– ‒ "2/3 Criteria were considered suspects 
and referred for glaucoma consultation: 
(1) global Moorefield’s Regression 
Analysis borderline or outside normal 
limits, (2) Nerve Fibre Index >30, and 
tonometry >21mmHg." 
– ‒ – ‒ 
Shahid et al.  
(2012)
49 
78% African 
American, 10% 
Caucasian, 6.7% 
Hispanic, 4.8% 
Other 
– ‒ 
Yes One 
Kiage et al.  
(2013)
53 
100% African Category 1 diagnosis (structural and 
functional evidence): 2 out of 3 of the 
following: VCDR >0.7, focal glaucoma 
disc changes, VCDR asymmetry (> 
0.2). Category 2 diagnosis (structural 
evidence with unproved field loss): 2 
out of 3 of the following: VCDR >0.8, 
focal glaucoma disc changes, VCDR 
asymmetry > 0.3. Category 3 diagnosis 
(optic disc not clearly seen): 1 of the 
following visual acuity < 3/60 and IOP > 
21 mmHg or visual acuity < 3/60 and 
evidence of glaucoma surgery or 
medical records confirming glaucoma 
morbidity. Glaucoma suspect: one of 
the following IOP > 23 mmHg, 1/3 of 
the glaucomatous optic neuropathy 
listed in category 2, glaucoma visual 
field defect only. Yes Three 
Gupta et al.  
(2013)
51 
100% Indian Glaucoma diagnosis based on disc 
findings VCDR of > 0.7 or focal 
neuroretinal rim defect. Yes 
– ‒ 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic Review and 
Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Table 3.5: Study Relevant Outcome Measures 
Author (Year) 
Specificity 
(%) 
Sensitivity 
(%) 
Percentag
e 
Glaucoma 
diagnosed 
Percentag
e Referral 
Rate 
Percentage 
of Image of 
Poor Quality 
Li et al. (1999)24 – ‒ – ‒ – ‒ – ‒ 18.8 
Yogesan et al. 
(1999)25 84.5 82.5 
– ‒ – ‒ – ‒ 
Eikelboom et al. 
(1999)19 71.5 67 
– ‒ – ‒ – ‒ 
Yogesan et al. 
(2000)28 87 100 
– ‒ – ‒ – ‒ 
Gonzalez et 
al.(2001)29 
– ‒ – ‒ 
7.9 
– ‒ 
13 
Sebastian et al. 
(2001)30 
– ‒ – ‒ 
2.7 
– ‒ 
4 
Wegner et al. 
(2003)31 
– ‒ – ‒ 
 
– ‒ 
9.4 
de Mul et al. 
(2004)36 58 82 4.6 11 
– ‒ 
Ianchulev et al. 
(2005)20 95.5 81.5 
– ‒ – ‒ – ‒ 
Kumar et al. 
(2006)21 98.8 38.1 
– ‒ – ‒ – ‒ 
Kumar et al. 
(2007)38 93.6 91.1 
– ‒ – ‒ – ‒ 
Pasquale  et al. 
(2007)
40 96 59 
– ‒ – ‒ – ‒ 
deBont et al. 
(2008)42 
– ‒ – ‒ – ‒ 
11 11 
Staffieri et al. 
(2011)46 
– ‒ – ‒ 
5 
– ‒ – ‒ 
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Anton-Lopez et 
al. (2011)44 
– ‒ – ‒ 
1.9 7.7 
– ‒ 
Khurana et al. 
(2011)45 
– ‒ – ‒ 
1.06 12.5 
– ‒ 
Shahid et al. 
(2012)49 
– ‒ – ‒ 
32 
 
– ‒ 
Ahmed et al. 
(2013)55 
– ‒ – ‒ – ‒ 
19.4 5 
Gupta et al. 
(2013)51 81.82 72.1 
– ‒ – ‒ – ‒ 
Kiage et al. 
(2013)53 89.6 41.3 14 
– ‒ 
24 
Verma et al. 
(2013)54 
– ‒ – ‒ 
31 31   
Arora et al. 
(2014)56 
– ‒ – ‒ 
44 
– ‒ – ‒ 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Table 3.6: Quality of Analysis for Costing 
Author 
(Year) Object Costs ($) Currency 
Tuulonen 
et al. 
(1999)23 Fixed Costs 
  
 
Fundus camera (1 unit) 200 FIM 
 
ISDN installation (3 units) 6.5 FIM 
 
Server computer (2 units for 5 
years) 
50 
FIM 
 
Software application (2 units for 
5yrs) 
50 
FIM 
 
Video slit-lamp (1 unit) 40 FIM 
 
Write off 10 years (3%) 40.62 FIM 
 
Use of teleophthalmology 
equipment 
24.372 
FIM 
 
Video conference equipment 84 FIM 
 
Write-off 5 years 18.342 FIM 
 
Automated perimetry – Humphrey 132 FIM 
 
Write off 10 years (3%) 15.474 FIM 
 
Other fixed costs 
 
 
 
Service and updating 5 FIM 
 
Line costs per month 3.672 FIM 
 
Premise 1.608 FIM 
 
Utilities 1.608 FIM 
 Other costs 7.133 FIM 
Yogesan 
et al.  Satellite phone 30000 EUR 
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Author 
(Year) Object Costs ($) Currency 
(2000)27 
  Mobile phone 3250 EUR 
Jin et al.  
(2003)34 Total expenditure capital 160260 CAN 
 
Operating costs per 1 year 348665 CAN 
 
Projected 2005 Costs 385226 CAN 
 
Operating costs amortized over 5 
years 32052 CAN 
 
Operating costs amortized over 5 
years per diabetic case 1231 CAN 
 
Professional and Lab Fees 291 CAN 
 
Costs per patient 1231 CAN 
 
Travel costs 805 CAN 
 Escort travel expenses 340 CAN 
Chen et al.  
(2004)35 Costs per detected case 10 US 
Ianchulev 
et al. 
(2005)20 
Costs per targeted glaucoma 
screening 60 US 
  Costs per detected case 1000 US 
Sogbesan  
(2010)43 Patient savings 2527 CAN 
Anton-
Lopez et 
al. (2011)44 Incremental Costs 24150 EUR 
 
Costs per detected case 1420 EUR 
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Author 
(Year) Object Costs ($) Currency 
 
Primary Care visit 15 EUR 
 
General Ophthalmic Visit 18 EUR 
 
Ophthalmic Visit with tests 52 EUR 
 Glaucoma Consultation 26 EUR 
Swierk et 
al. 
(2011)47 Medical Care 291.21 EUR 
 
Accommodation costs 280 EUR 
 Costs per patient 288.72 EUR 
Ahmed et 
al.  
(2013)55 
Equipment costs (digital retinal 
camera, Tonopen and computer) 46000 US 
Vendor 
Estimates 
(2014)10, 11 OCT 
48,000 – 
49,000 CAN 
 Slit Lamp 
7,420 - 
19,990 CAN 
    
 Tonometer   
 Slit lamp mounted 
1,400 – 
2,400 CAN 
 Non-contact 8,995 CAN 
    
 Retinal Camera 
27,900 – 
27, 995 CAN 
 Visual Field Analyser 
16,340 – 
32,420 CAN 
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Author 
(Year) Object Costs ($) Currency 
 TOTAL RANGE: 
89,703.53 
- 
123,164.55 US 
Ocular 
Health 
Network 
(2014)12 Imaging Transfer Service 70/Month CAN 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
 
Table 3.7: Teleglaucoma Estimated 2014 Unit Costs 
Author (Year) 
Cost per 
detected case 
($US) 
(Adjusted for 
inflation to 
2014 costs) 
Inflation 
Rate 
(%) 
Cost per 
patient 
($US) 
(Adjusted 
for inflation 
to 2014 
costs) 
Inflation 
Rate 
(%) 
Jin et al. (2003)34 – ‒ – ‒ 1434.63 25.49 
Chen et al. 
(2004)35 13.03 30.32 – ‒ – ‒ 
Ianchulev et al. 
(2005)20 1262.02 26.2 – ‒ – ‒ 
Anton-Lopez et al. 
(2011)44 2020.96 5.89 – ‒ – ‒ 
Swierk et al. 
(2011)47 – ‒ – ‒ 410.91 5.89 
Mean costs 1098.67   922.77   
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Table 3.8: Study Ophthalmic Examinations  
Author (Year) Examination tests 
Li et al. (1999)24 Optic disc photographs, VCDR 
Yogesan et al. (1999)25 VCDR 
Eikelboom et al. (1999)19 VCDR 
Yogesan et al. (2000)28 Fundus images, H/VCDR, radial rim measurements 
Gonzalez et al.(2001)29 Fundus images 
Sebastian et al. (2001)30 Visual acuity, IOP, FDT, optic nerve head 
photographs 
Wegner et al. (2003)31 HRT, IOP, OCT 
de Mul et al. (2004)36 IOP, nerve fibre indicators 
Ianchulev et al. (2005)20 HVF, visual acuity 
Kumar et al. (2006)21 
IOP, CCT, ACT 
Kumar et al. (2007)38 
IOP, FDT, VCDR, disc asymmetry, visual field, 
fundus photographs 
Pasquale  et al. (2007)40 IOP, CDR, Humphrey visual field, comprehensive 
eye examination 
deBont et al. (2008)42 Nerve fiber indicators, fundus photographs, IOP 
Staffieri et al. (2011)46 
Visual acuity, refractive status, visual field testing, 
IOP, CCT, stereoscopic optic disc photographs 
Anton-Lopez et al. 
(2011)44 
IOP, HRT, nerve fibre indicators 
Khurana et al. (2011)45 -- 
Shahid et al. (2012)49 
IOP, optic nerve head appearance and asymmetry, 
nerve fibre layer dropouts 
Ahmed et al. (2013)55 Fundus images, CDR, IOP 
Gupta et al. (2013)51 Fundus photographs 
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Kiage et al. (2013)53 
Slit lamp examination, focal glaucoma damage, 
VCDR, IOP, FDT, fundus images, visual fields 
Verma et al. (2013)54 
Stereoscopic optic nerve images, visual fields, 
ancillary tests, IOP, OCT, and HRT 
Arora et al. (2014)56 
OCT, HRT, stereo-nerve photographs, FDT, HVF, 
OCT, IOP 
Legend: VCDR= vertical cup-to-disc ratio, HCDR= horizontal cup-to-disc ratio, 
IOP= intraocular pressure, FDT= frequency doubling technology, CCT= central 
corneal thickness, HRT= Heidelberg Retinal Tomography, CDR=cup-to-disc 
ratio, HVF= Humphrey Visual Field, ACT= anterior chamber depth, POAG= 
primary open angle glaucoma, OAG= open angle glaucoma 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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3.7 Figures 
Figure 3.1: PRISMA Diagram 
 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Figure 3.2: HSROC Curve 
 
Footnote: Thomas S-M, Jeyaraman M, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta MS (2014) The 
Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma Screening: A Systematic 
Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi:10.1371/journal.pone.0113779 
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Chapter 4 The cost-effectiveness of teleglaucoma versus in-
person examination 
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4.1 Introduction 
The burden of vision loss on the Canadian economy is $15.8 billion per 
year in which 55% is allocated to direct health care costs.1 Sixty-five per cent of 
adults with partial or full vision loss are unemployed, which translates to $4.06 
CAN billion annually of lost earnings.1 In the United States, vision loss costs over 
$35 billion for direct costs and loss of productivity.2 Glaucoma is the major eye 
disease leading to irreversible vision loss. The economic burden of glaucoma 
alone on the American economy is $2.9 billion.2  
Screening for glaucoma is important. Glaucoma is a public health concern. 
It has a prolonged asymptomatic phase and if detected early and with effective 
therapy blindness can be prevented.3 Screening has shown to be effective 
specifically in high-risk populations such as patients older than 50 years and 
black populations.3,4 Currently, screening for glaucoma occurs passively within 
routine ocular examination at the optometrist and/or ophthalmologist clinics. This 
is referred to as “in-person examination.”5,6 “Passive” screening is when the 
patients come to the doctor and “active screening” is when the healthcare 
providers actively draw patients in for screening. Active screening on a 
population base, where health care providers provide outreach programs to draw 
patients in for screening, rarely occurs.5 Mainly research or community groups 
conduct population-based screening sporadically and there is no mandated 
active screening that occurs at a population level.5 There are two main obstacles 
with population-based screening: firstly, there is a lack of an efficient screening 
test and secondly, there is insufficient economic evidence.5  
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Teleglaucoma is an innovative screening test that has the potential to be a 
sufficient screening tool. Chapter three of this thesis discussed the effectiveness 
of teleglaucoma and found implementation of teleglaucoma improved the 
detection of glaucoma on a population level. It was reported by Tuulonen et al 
that patients were satisfied with teleglaucoma service as it successfully reduced 
patient costs by 92%, saved patient time by 92%, and there was a 97% reduction 
in patient travel.7 A recent study by Thomas et al synthesized the effectiveness of 
teleglaucoma and found teleglaucoma was effective at screening negative 
cases.8 The technology gave poor quality images in only 10.4% of images.8 It 
improved access to ophthalmologist and had a referral rate of 12.5% to the 
ophthalmologist.8 This chapter will discuss the economic evidence of 
teleglaucoma’s effectiveness and the objective is to determine the cost-
effectiveness of teleglaucoma as a screening device for glaucoma in comparison 
to in-person examination. 
Vision impairment associated with glaucoma negatively affects one’s 
Health-Related Quality of life (HRQoL). Preference-based HRQoL is referred to 
as the individual’s perception of his/her disease state and its effect on his/her 
quality of life.9 HRQoL can be quantified using utility values which range from 0 
indicating death to 1 indicating excellent health with complete functioning.9 
Therefore, glaucoma patients are hypothesized to have a lower utility value and 
HRQoL than healthy people.  
For cost-effectiveness analysis it is necessary to translate effect data into 
Quality Adjusted life Years (QALYs) to allow easy comparison between different 
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interventions. QALY incorporates both quality and quantity of life, specifically life 
expectancy and quality of remaining life years.9,10 QALYs are the amount of 
years in a person’s life that is adjusted to represent remaining life years in perfect 
quality.9,10 It weighs the time spent in different health states. Consequently, 
teleglaucoma has shown increased ability to detect glaucoma in rural Alberta, 
allowing for treatment of cases in remote areas that would have not necessarily 
be treated. In addition, it allows early detection of glaucoma to delay the 
progression of disease. Thus, it is suggested that teleglaucoma increases 
patients’ utility values, improves their HRQoL, and provides more QALYs 
compared to standard in-person care.8     
With implementation of any new technology and service comes an 
additional cost. Thomas et al reported that teleglaucoma had a mean cost per 
patient screened of $922.77 (US) and a mean cost per detected case of 
$1098.67 (US).8 However, there are no economic evaluations in literature which 
examine the cost-effectiveness of the use of telemedicine for glaucoma 
screening. Thus, the purpose of this cost-effectiveness analysis (CEA) was to 
examine the costs and benefits of teleglaucoma and to determine the cost-
effectiveness of teleglaucoma as a screening device for glaucoma in comparison 
to the standard of care, which is in-person examination. This CEA took a third-
party payer and Ministry of Health perspective. The targeted population included 
people living in rural Alberta who are at-risk of glaucoma. The long term benefits 
of teleglaucoma which included prevention of blindness from glaucoma was also 
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assessed. A portion of this chapter has been conditionally accepted for 
publication and is currently under second review.11 
4.2 Methods 
4.2.1 Study Design 
A cost-effectiveness analysis was conducted using healthcare provider 
perspectives within rural Alberta, Canada.11 Statistics Canada defines rural 
populations as areas with persons living outside centers with a population of 
10,000 or fewer and outside areas with fewer than 400 persons per square 
kilometre.12 Other than certain parts of Edmonton and Calgary, the majority of 
communities in Alberta are rural areas. It has been documented that 95% of 
Alberta is rural area.13 The study population are patients at-risk of glaucoma, 
which includes those with diabetes and/or hypertension, family history of 
glaucoma, older adults, and concurrent ocular conditions in rural Alberta. 
Targeting at-risk populations has been suggested as a more efficient method of 
detecting glaucoma.14 Teleglaucoma screening in the model was applied to a 
population aged 50 years and older at a frequency of one screening per year.11 
The model assumed teleglaucoma has the capacity for 300 people per year.7,11 
The time horizon was 30 years as glaucoma is a chronic, life-long condition. 
4.2.2 Teleglaucoma Definition 
 There are several standardized characteristics of Teleglaucoma (Table 1). 
Teleglaucoma consists of standard ophthalmic instruments used for screening. 
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The main instruments are the fundus cameras, Heidelberg Retina Tomograph 
(HRT), and the optical coherence tomography (OCT), which produce digital 
imaging of the retina.15-17 In addition, tonometers are used to measure the 
intraocular pressure. Gonioscopy, a test used to determine the angle between 
the iris and cornea, and perimetry, the visual field test, are also used for 
teleglaucoma screening. The retinal images and test results are sent via 
electronic systems. Thus, the essential part of teleglaucoma is the information 
systems which include the Secure Diagnostic Imaging (SDI) systems, ISDN 
installations, computers, and videoconferencing equipment. These equipment 
would be set up within a small clinic in the vicinity of the rural population.  
Teleglaucoma requires at minimum technicians who are trained to screen 
the patients and to transfer the files to the ophthalmologist.7,15 The teleglaucoma 
process is a quick process; the mean screening time is 8.8 minutes.17 Once the 
images are sent to the ophthalmologist, the images and test results are then 
used for diagnosis. If the patient is diagnosed or determined as a glaucoma 
suspect, the patient is then referred to the ophthalmologist for a full consultation 
and receives the standard of care for glaucoma treatment.       
4.2.3 Comparator Definition 
The comparator for this study was in-person examination, the standard 
screening that occurs at the optometrists and/or ophthalmologists office. This 
type of screening is a more “passive” type of screening where patients have their 
routine eye examination; it is not necessarily a targeted screening for glaucoma. 
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However, patients with known risk-factors for glaucoma are screened specifically 
for glaucoma.  
In-person examination uses the standard diagnostic instruments as 
described for teleglaucoma with the exception of the imaging transferring 
software.5,15 The staff required are optometrists, technicians, and 
ophthalmologists.8,15 For in-person examination, the patient visits the optometrist 
in person at the clinic for a full examination of the eye. If glaucoma is suspected 
the patient is then referred to an ophthalmologist. The ophthalmologists will 
perform several more diagnostic tests to diagnose glaucoma. Based on the 
diagnosis, the patient will receive treatment in accordance with the standard of 
care for glaucoma. If glaucoma is suspected the patient will continue to be 
monitored by the ophthalmologists.6 For this study, in-person examination was 
considered “no-screening or passive screening” intervention. It is also the “do-
nothing” approach as it is the standard of care for glaucoma screening.  
4.2.4 Markov Model   
Markov Modelling was used to model the four glaucoma health states 
(mild, moderate, severe, and blind).11 TreeAge Pro 2009 was used to build the 
Markov Model (Appendix 4) consisting of the costs, benefits, and transitional 
probabilities of different health states. Incremental cost-effectiveness ratios 
(ICER) were developed in dollars per QALYs. Effectiveness was measured in 
QALYs and costs were used in Canadian dollars. The cycle for the Markov Model 
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represented one year and the ICERs following 30 cycles were established.11 
Assumptions that were used in the model is that:  
 Individuals with glaucoma who were screened negative with teleglaucoma 
were assumed to be detected at the same probability of at-risk 
populations. They will have the same probabilities as being detected 
through in-person care. 
 Individuals without glaucoma who were correctly screened negative can 
either remain at risk or transition to mild glaucoma at the transitional 
probability without treatment.  
 Individuals with glaucoma who were seen by in-person  care who were 
incorrectly detected as negative for glaucoma were assumed to have 
transitional probabilities based on untreated glaucoma. 
In application, the implementation of teleglaucoma does not replace in-
person care, but rather is additional to in-person care. Thus, the teleglaucoma 
arm of the decision tree, is displayed with combined costs and effect data of 
teleglaucoma and in-person care (Appendix 4). This model provides an overall 
outlook on total costs to run both programs at the same time in comparison to in-
person examination. 
4.2.5 Health States 
 There are four health states associated with glaucoma: mild, moderate, 
severe, and end-stage glaucoma, which is blindness.6,18 Mild glaucoma is 
characterized by abnormalities of the optic nerve without any visual field 
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abnormalities. Moderate glaucoma is characterized by damage to the optic nerve 
and some peripheral vision loss. Severe glaucoma is the advanced stage of 
glaucoma characterized by severe optic nerve damage and advanced peripheral 
vision loss.11 Blindness is characterized by a visual acuity of 20/200 or worst.19 
Blindness in this study refers only to blindness due to glaucoma as opposed to 
blindness due to other causes.    
Glaucoma is a chronic condition with progressive ocular damage and 
vision loss. Patients will progress from one stage to the next and with successful 
treatments the patient will remain in the current health state. There is no cure for 
glaucoma and thus patients cannot transition to healthier states. Once a patient 
is blind, the patient will remain blind.  
The Markov Model transitional states can be found in Figure 4.1. The 
progression of glaucoma through the health states are at higher probabilities 
when glaucoma is not detected early, not diagnosed, and/or left untreated (Table 
4.2). The transitional probabilities are not time-dependent but rather depend on 
management of disease through treatments or no treatments.9 If managed 
appropriately with proper medications and treatment the progression of glaucoma 
is delayed.6 Patients who were detected positive with either teleglaucoma or in-
person care were assumed to be treated. There was a 75% compliance with 
treatment and treatment efficacy was 50% as reported by literature.9 Because 
the progression of glaucoma is dependent on individual characteristics and 
compliance to treatment, there is a degree of uncertainty with the transitional 
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probabilities. As a result, beta distributions will be applied to transitional 
probabilities and assessed through Probabilistic Sensitivity Analysis.       
4.2.6 Costs 
Technology Costs 
There are three main components of teleglaucoma and each are associated 
with costs: human resources, information technology, and diagnostic equipment 
(Table 4.1).15 The synthesis of teleglaucoma costs derived by Thomas et al. and 
the Ministry of Health Medical Procedures List were used as costing data 
sources.17,21  Additional base costs of the teleglaucoma technology were 
reported by a study on effectiveness of tele-ophthalmology for glaucoma by 
Tuulonen.7 All costs were converted to 2014 Canadian dollars and adjusted for 
inflation at 2.05%.17, Future costs were discounted at a 3% rate.9,10 
Costs were divided by the number of patients serviced to determine the costs 
per patient and also to account for the differences in coverage between in-person 
care and teleglaucoma. Teleglaucoma was reported to service 300 people per 
year, while in-person care was reported to have 1379 glaucoma visits per year in 
rural Alberta.7,22 Teleglaucoma requires training of graders on how to use the 
technology. The costs for training includes labour costs for two (full-time 
equivalents) trainers at the average Alberta salary ($50,000) and training 
resources.23 Costs assumed a maximum two week training session and paid for 
trainees. The direct costs of teleglaucoma included the costs of equipment, set-
up, overhead, utilities, and labour (Table 4.3). 
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 Health State Costs 
There are costs associated with living with glaucoma. Each health state 
requires different levels of medical treatments and drug therapies. In addition, 
each is associated with indirect costs such as health system costs, loss of 
productivity, additional vision aids, and modifications to home or work to 
compensate for vision loss. The costs associated with each health state was 
given by Lee et al study on resource consumption at different levels of severity of 
glaucoma.23 All stages include the following direct costs: visits to 
ophthalmologists and/or optometrists, Humphrey Visual Field tests, medications, 
surgeries, and glaucoma testing (gonioscopies, nerve fiber thickness analysis 
and intraocular pressure diurnal).24  
The stage at-risk was assumed to be equal to “Stage 0” of Lee’s criteria 
which constitutes a glaucoma suspect patient who is at-risk of glaucoma, but 
does not meet the criteria for clinical diagnosis.24 The costs associated with the 
“at-risk” stage includes routine optometrists and/or ophthalmologist visits. The 
costs of blindness were reported by the Canadian National Institute for the Blind 
(CNIB).25 The costs of blindness includes direct costs (vision aids and 
treatments) as well as indirect costs such as loss of productivity, caregiving 
assistance, etc. Table 4 summarizes the costs associated with each health state. 
The costs were derived to represent Alberta. In rural Alberta, there are limited 
nearby ophthalmic resources and travelling when blind becomes a costly 
endeavor.13,22 Thus, uncertainty in costs of blindness was addressed using 
sensitivity analysis.  
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Patient Costs  
Teleglaucoma has been reported to have direct reduction in costs to patients 
specifically in travel time, doctor wait times, assessment times, and 
transportation costs.7,17,26 These costs were added to the costs associated with 
teleglaucoma and in-person care to be included in the analysis. The costs to 
patients for each intervention is summarized in Appendix 5. The following 
assumptions were applied to estimate costs:  
 Travelling costs were assumed to be costs associated with personal 
automobiles and did not account for potential public transit costs. Distance 
travelled was converted into costs using current 2014 gas prices in Alberta 
($1.26/L).27 
 The Grossman Health Model regarding the consumption and investment 
demand for health was applied.9,10 It is assumed there is a trade-off 
between time spent producing health and time spent producing other 
goods. Any investments in health are reduced by time lost to illness. Thus, 
there is a monetary value to time. This monetary value will be assumed as 
wage rate. Time spent waiting for doctor and travelling to and from clinics 
were converted to loss of productivity using Alberta average hourly wage 
$29.54.23      
Total Costs 
All costs were summed into initial and incremental costs and cost per patient 
screened was determined (Appendix 6). The initial costs were the fixed costs 
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such as the initial set up fees. The incremental costs included the patient costs, 
service costs, labour costs and costs associated with each health state. All costs 
were converted to present value Canadian dollars and future costs were 
discounted at a 3% rate. The willingness to pay applied was $40,000/QALY as 
reported by literature for ophthalmic interventions.25 Uncertainties in estimated 
costs were addressed using probabilistic sensitivity analysis and applying 
gamma distributions (Appendix 7).  
4.2.7 Effectiveness 
 The effectiveness of teleglaucoma is defined by its ability to detect 
glaucoma. This is measured as specificity and sensitivity of the equipment 
devices and the probability of being correctly screened as glaucoma positive, and 
correctly screened as glaucoma negative. The sensitivity of teleglaucoma is 
particularly important because it incorporates the false negatives. The false 
negatives are the patients who have the disease and are incorrectly detected as 
a negative test. This patient group will be told they do not have the disease and 
continue living as normal. However, with glaucoma, this is particularly crucial to 
avoid. Glaucoma is a silent thief of vision and if left untreated patient can lose 
substantial visual acuity as well as suffer from visual defects. Thus, the sensitivity 
of teleglaucoma is important to prevent glaucoma cases from leaving the clinic 
without appropriate medical care. 
Several studies have tested the accuracy of teleglaucoma devices with 
gold standard diagnostic tools, but have reported results in kappa statistic 
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agreements.28,29 However, not all studies used the same equipment and devices. 
In addition, most studies were performed outside of Canada, specifically in 
Kenya or India. From the literature and chapter 3, the specificity and sensitivity of 
teleglaucoma were reported as 86.5% and 78.6% respectively.17  
 The second aspect of effectiveness is the ability of screening devices to 
detect glaucoma at its early stages. The probabilities of each stage of glaucoma 
at time of screening were derived from a study examining the use of 
teleophthalmology.30 Corresponding with the hypothesis, a greater proportion of 
individuals (46%) at mild glaucoma stage were detected with teleglaucoma.30 
The effectiveness of no screening (in-person care) was given by reported 
probability of glaucoma being detected in routine in-person care.1 Fifty per cent 
of glaucoma patients are undetected and are unaware of their disease state.1 
The other 50%, when presented at in-person care, these glaucoma patients are 
usually at the advanced stages of the disease with progressive vision loss. The 
probabilities of each glaucoma health state detected at time of in-person care 
was derived from CNIB’s Cost of Vision Loss Report.1 Table 4.5 displays the 
probabilities of glaucoma detection with each intervention. It also displays those 
who were detected and at which health state they were in at time of screening.1        
The effectiveness of teleglaucoma was also measured in its reduction of 
travel time and improved access to care for people living in rural Alberta and 
other remote, underserviced areas. Specifically, teleglaucoma has been 
associated with savings of 4906km in travel distance and 61.23 hours of 
travelling time.17,26,31 The length of time spent at the doctor visit (includes wait 
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time and assessment time) with teleglaucoma was 78 minutes (~1.3 hours) 
whereas with in-person care it took 115 minutes (~1.91hours).17,26    
 4.2.8 Utilities  
The effectiveness of teleglaucoma as stated above is mainly seen by its 
early detection, to initiate early treatment, to prevent progression of disease into 
advanced stages. Thus, its beneficial for preserving vision. Living in each 
glaucoma stage, specifically with vision loss, negatively affects one’s HRQoL. 
With each glaucoma health state there is a progression of the disease. Thus with 
disease progression, there is a decline in HRQoL and decreased utility value. 
The utility value for each health state is 0.87, 0.79, 0.64, and 0.5, for mild, 
moderate, severe, and blindness, respectively.32,33 These values are converted to 
QALYs, as the ultimate unit of effectiveness for the cost-effectiveness analysis. 
QALY incorporates both quality and quantity of life, specifically life expectancy, 
and quality of remaining life years. QALYs are the amount of years in a person’s 
life that is adjusted to represent remaining life years in perfect quality.9 It uses 
weights on time spent in different health states. Thus one year living in blind state 
(utility value =0.5) is equivalent to half a year living in perfect health (utility = 1.0) 
which means blind state is equivalent to 0.5 QALYs. Likewise the effect gained 
from living in mild, moderate, and severe glaucoma is thus 0.87 QALYs, 0.79 
QALYs, and 0.64 QALYs, respectively.    
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4.2.9 Analysis Plan 
 This study analyzed the incremental costs, the incremental effect, and the 
ICER for teleglaucoma versus in-person examination.  Deterministic and 
probabilistic sensitivity analyses were performed to assess the factors affecting 
cost-effectiveness. Markov Cohort Analysis by 30 stages was conducted to 
demonstrate the accumulated rewards, costs, and probabilities after 30 years. 
Monte Carlo Simulations with the application of second-order uncertainties and 
gamma and beta distributions were performed with 1000 samples. In addition, 
the analysis generated the distribution of the ICERs by probability, the cost-
effectiveness scatterplots, and the impact of willingness-to-pay on the probability 
of ICERs within an acceptability curve.    
Sensitivity Analysis   
 Certain parameters within the model have uncertainties as discussed 
above. Sensitivity analysis was conducted to determine if the uncertainties affect  
the stability of the results. Deterministic sensitivity analysis was used to 
determine any effects of uncertainty of costs of blindness, transitional 
probabilities (at-risk to mild glaucoma and severe to blind states), and probability 
of glaucoma within the population. The estimated probability of glaucoma 
contains uncertainty as most cases of glaucoma go undetected and also there is 
potential uncertainty in the generalizability of prevalence rates to rural Alberta. 
These parameters were varied by 20% within the analysis (Table 4.2, Table 4.4). 
Tornado diagrams were used to give parameters that have the most effect on 
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cost-effectiveness. Probabilistic Sensitivity Analysis was also conducted to 
assess uncertainty using gamma and beta distributions for uncertain costs and 
probabilities respectively (Appendix 7).  
4.3 Results 
4.3.1 Incremental Cost-Effectiveness Ratio 
The ICER for teleglaucoma screening versus in-person examination (no-
screening) was established in TreeAge 2009 displaying the ratio of incremental 
costs (Canadian dollars) and incremental effectiveness (QALYs) at a discounted 
rate of 3% (Table 4.6).11 
Teleglaucoma demonstrated to be more cost-effective than in-person care 
for detecting glaucoma; the ICER was $47.60/QALY.11 This means that spending 
an additional $47.60 for each patient screened with teleglaucoma will give an 
additional QALY in comparison to in-person screening. The results also indicated 
that teleglaucoma costs less than in-person screening when adjusted for per 
patient costs and also it was more effective.  Thus, the no screening option (in-
person examination) is dominated by teleglaucoma screening (Figure 4.2). In 
most cases, cost-effectiveness analysis are not performed under these 
conditions (more effective, less costly). However, this study included long-term 
effectiveness, which was not investigated previously in literature and thus this 
analysis has established new information.   
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4.3.2 Markov Cohort Analysis 
Based on Markov Model principles, transitional probabilities are 
independent of previous health states and they determine the proportion of 
individuals who transition to other heath states per cycle.9,10 Markov Cohort 
Analysis was conducted with 30 cycles representing 30 years.  
After 30 years, teleglaucoma showed rewards for people with glaucoma 
who were initially screened positive. The total reward for teleglaucoma was 15.7 
QALYs, which was 1.1 less than rewards from in-person care (Table 4.7).11 
However, the cumulative costs per patient for in-person care was almost 3.5 
times that of teleglaucoma after 30 years, which indicated the cost-saving 
associated with teleglaucoma screening. For both interventions, after 30 years 
the majority of patients were blind, however it was 24% less in teleglaucoma 
screening.11 Teleglaucoma also had a greater probability of preventing glaucoma 
patients from progressing as 15% remained in the mild stage of glaucoma 
compared to 2% with no screening.   
The Markov Probability Analysis displayed how the probability of each health 
state changes over the study time horizon in patients who were detected positive 
for glaucoma with either intervention (Figure 4.2).11 The results demonstrated 
that the probability of being at-risk for glaucoma and moderate glaucoma over 30 
years (30 stages) remains relatively the same in teleglaucoma versus in-person 
care. The probability of being in mild glaucoma is higher with teleglaucoma 
screening, but in both interventions this probability declines with time. Similar to 
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previous results, the probability of being blind was greater with in-person care 
than with teleglaucoma (the concave down increasing trend of the blind state 
curve in Figure 4.2b displays a closely exponential trend).11 This indicated that 
teleglaucoma is more effective at preventing the probability of blindness in 
glaucoma patients.  
4.3.3 Deterministic Sensitivity Analysis  
Deterministic sensitivity analysis was used to determine the effects of 
uncertainty on the ICER results. One-way sensitivity analyses were performed on 
the following variables: the costs of blindness, the transitional probabilities for at-
risk to mild glaucoma and severe glaucoma to blind states (with and without 
treatment). The results demonstrated that changing (+/- 20%) the costs of 
blindness caused changes in the ICERs for both strategies. Teleglaucoma had 
higher ICERs than inpatient screening (Figure 4.3).11 The cost-effectiveness of 
teleglaucoma is affected by the costs of blindness: as costs of blindness 
increases the ICER for teleglaucoma becomes smaller. 
As shown in Figure 4.3d, the ICERs of inpatient screening remained 
unchanged while the ICER of teleglaucoma increased very slightly as the 
transitional probability of blindness increased.11 With better treatment of 
glaucoma, which prevents patients from becoming blind, teleglaucoma becomes 
more cost-effective (Figure 4.3d).11   
The tornado diagram gives the parameters with the most effect on cost-
effectiveness at a willingness to pay of $40,000/QALY (Figure 4.4).11 It displays 
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that the uncertainty within the prevalence of glaucoma has the most effect on the 
ICER and it has the largest range of net monetary benefits. The results suggest 
the transitional probabilities for at-risk to mild and severe to blind have more of 
an effect on the cost-effectiveness of teleglaucoma as well as the cost of 
blindness. Whereas, the transitional probability for severe to blind without 
treatment and at-risk to mild with treatment had less effect on the cost-
effectiveness of teleglaucoma.  
4.3.4 Probabilistic Sensitivity Analysis   
Gamma and beta distributions were applied to the Markov Model. Monte 
Carlo Simulation second order was conducted and the statistics report gave a 
mean cost of teleglaucoma as $866.90 ± 113.10 per patient screened compared 
to in-person screening which has a mean of $4419.8 ± 1044.70. The results 
showed teleglaucoma costs less per patient than in-person screening. 
The results of the Cost-effectiveness scatterplot demonstrate that there is 
a greater uncertainty with the costs and effectiveness of “in-person screening” 
(in-person care) as the dots of the graph are widely spread apart giving costs 
from approximately $3K-8K (Figure 4.4).11 However, there is less uncertainty with 
the costs of teleglaucoma, since the dots are tightly plotted around $1K (Figure 
4.4).11 This means that the ICER of in-person care is more sensitive to the costs 
than the ICER of teleglaucoma whereas teleglaucoma ICER is more sensitive to 
the effectiveness in comparison to in-person care. The results of the sensitivity 
analysis on willingness to pay demonstrate that neither teleglaucoma nor in-
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person care is sensitive to changes in WTP as the line remains relatively 
constant as WTP changes (Figure 4.5).11 Only after WTP increases above 
$60,000, the probability of cost-effectiveness for teleglaucoma becomes slightly 
less cost-effective versus in-person screening which becomes slightly more cost-
effective. However, in comparison to in-person screening teleglaucoma is 100% 
more cost-effective.      
4.4 Discussion 
Teleglaucoma is beneficial to remote areas as the physician is not 
required to see patients in person. This reduces wait times and shortens the 
length of ophthalmic consultations. Teleglaucoma avoids long distance travel and 
time wasted on commuting. Our results demonstrated the direct benefits to 
patients was a cost savings of ~$2474.60 with teleglaucoma. The early detection 
approach of teleglaucoma successfully reduced the probability of patients at the 
blind stage of glaucoma by 24% and maintained 13% more patients at the mild 
stage glaucoma in comparison to in-person care. The long-term benefits of early 
detection was confirmed by this CEA with greater cumulative rewards and cost 
savings 30 years post-detection. When assessed on its own, teleglaucoma was 
more cost-effective than in-person care with an ICER of -$27,460 per QALY (cost 
per patient serviced) meaning teleglaucoma saved $27,460 per QALY gained 
relative to in-person examination. The large direct patient savings and reduced 
costs of blindness due to preservation of vision, mainly accounted for its 
effectiveness. The ICER of teleglaucoma was only sensitive to the probability of 
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glaucoma. This is logical since positive predictive values of screening tools 
fluctuate with changing prevalence rates and changing prevalence rates will alter 
the probability of glaucoma. As the probability of having glaucoma increases, 
teleglaucoma had greater cost-effectiveness. 
At a willingness to pay of $40,000/QALY, teleglaucoma is cost-effective 
when compared with in-person care.25 In addition, the World Health Organization 
provides the threshold for cost-effective interventions: an intervention is 
considered cost-effective if the ICER associated with implementation of the 
intervention is less than the country’s GDP.34 Teleglaucoma has an ICER below 
Alberta’s GDP and thus, teleglaucoma is cost-effective for Alberta’s population.    
Several studies have analyzed the effectiveness of teleglaucoma in terms 
of its ability to detect glaucoma and proposed reduction in direct patient costs, 
however, none have produced a complete cost-effectiveness analysis.17 Analysis 
of teleophthalmology for other ocular conditions such as diabetic retinopathy, 
have also shown to be cost-effective with ICERs of $1320/QALY in a similar rural 
setting based on the data of 326 patients from rural India.35 
The strength of this study is it indicated that although the base cost of 
teleglaucoma is large, the variable cost is lower per year. In return, the benefits 
outweigh costs over time. In addition, this study includes indirect costs such as 
loss of productivity and opportunity costs of time. By including the patient, the 
healthcare provider, as well as the Ministry of Alberta perspectives, a societal 
perspective is developed providing a broad scope on the cost-effectiveness of 
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teleglaucoma. This CEA is focused on screening for a targeted population who is 
above the age of 50 years and at-risk of glaucoma in rural Alberta, which is 
another strength of this study. Mass screening of total populations are not cost-
effective as it wastes resources with small benefits. In addition, this CEA applied 
Markov Modelling to illustrate the progression of glaucoma through transitional 
health states over time. This is beneficial to predict the long-term benefits of 
teleglaucoma. Costs were also discounted at a 3.0% rate to account for future 
value. Most studies have reported only the patient’s present benefits at time of 
the teleglaucoma screening, but have not analyzed the aftermath. Thus, with a 
time horizon of 30 years this CEA contributes to literature by illustrating 
teleglaucoma enables early detection, and, as a result, it delays the progression 
of glaucoma and preserves vision.   
One of the limitations for the CEA is that because no studies have 
analyzed the long-term benefits of teleglaucoma, estimates of transitional 
probabilities were derived from non-teleglaucoma studies. In addition, there is a 
lack of RCT data on teleglaucoma as most studies are observational. Of the 
observational studies that did look at the effectiveness of teleglaucoma, most 
focused on diagnostic accuracy, patient satisfaction, and reduced patient costs, 
but did not examine clinically relevant outcomes such as reduction in patients 
with vision loss. 
In conclusion, a cost-effectiveness analysis of teleglaucoma was 
successfully performed to demonstrate that implementing teleglaucoma in rural 
Alberta and targeting at-risk population is cost-effective in comparison to no 
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screening. Early detection of glaucoma allows necessary medical care to prevent 
progression of the disease. Glaucoma is a chronic progressive disease with no 
cure and thus this CEA provides valuable prognosis information. Teleglaucoma 
can have long-term benefits on preservation of vision in those with glaucoma.      
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4.6 Tables 
Table 4.1: Standardized Teleglaucoma Equipment  
Human Resources Information 
Technology 
Screening 
Equipment 
Examinations 
Ophthalmic 
technicians, 
Physicians, 
glaucoma 
specialists/ 
ophthalmologists, 
Graders, 
Optometrist 
Secure Diagnostic 
Imaging (SDI) 
system, 
Videoconferencing 
equipment, 
Computer systems 
and software 
Retinal camera, 
Tonometer, 
Devices to 
measure central 
corneal 
thickness, 
Frequency 
Doubling 
Technology 
(FDT) or 
Humphrey Visual 
Field test, 
Optical 
Coherence 
Tomography, Slit 
lamp, 
Gonioscope, 
Retinal camera, 
Devices to 
measure central 
corneal 
thickness 
Medical & family 
history, Visual 
acuity, IOP, 
CCT, OCT, Slit 
lamp, 
Gonioscopy, 
Visual field, Pupil 
equal  and 
reactive to light 
(PERL) or 
relative afferent 
pupillary defect 
(RAPD), Fundus 
photographs, 
Ancillary tests 
Footnote: Thomas S-M, Jeyaraman MM, Hodge WG, Hutnik C, Costella J, Malvankar-Mehta 
MS. (2014) The Effectiveness of Teleglaucoma versus In-Patient Examination for Glaucoma 
Screening: A Systematic Review and Meta-Analysis. PLoS ONE 9(12): e113779. doi: 
10.1371/journal.pone.0113779. pmid:25479593 
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Table 4.2: Transitional Probabilities for Glaucoma Health States 
  
Health States 
Transitional 
Probability 
Sensitivity 
Analysis 
Range 
 
Reference 
 
T
re
a
te
d
 
At-Risk to Mild 
Glaucoma 
0.20 0.16-0.24 Stein, 201235 
Mild to Moderate 
Glaucoma 
0.04  
Moderate to Severe 
Glaucoma 
0.10  
Severe Glaucoma to 
Blind 
0.15 0.12-0.18 
 
U
n
tr
e
a
te
d
 
At-Risk to Mild 
Glaucoma 
0.48 0.38-0.58 Fechtner, 
200436 
Mild to Moderate 
Glaucoma 
0.26  Chen, 201437 
 
Moderate to Severe 
Glaucoma 
0.5  
Severe Glaucoma to 
Blind 
0.5 0.4-0.6 Fechtner, 
200436 
Table 4.3: Direct Costs of Teleglaucoma and in-person Care  
 Teleglaucoma in-person Care 
 Total Fixed Costs ($) 
Set-up (Service and 
Training)  
416,600 243,146 
Technology Equipment 1,256,142 329,833 
 Variable Costs ( $ costs per patient screened) 
Labour  348 248.98 
Service 370.89 309.90 
Derivation of costs are found in Appendix 8. 
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Table 4.4: Costs associated with each health state 
Health State Costs ($) Sensitivity Analysis 
At-Risk  623  
Mild Glaucoma 1480  
Moderate 
Glaucoma 
3682  
Severe 
Glaucoma 
4975  
Blindness 33666 26,932.80 - 40399.20 
Derivations of costs can be found in Appendix 9.    
 
Table 4.5: Probabilities of glaucoma detection and associated health states 
 Probability of 
Being Detection 
Probability of each health state 
detected 
 Sensitivity Specificity At-
risk 
Mild Moderate Severe Blind 
Teleglaucoma 0.59 0.96 0.03 0.46 0.5099 0.0001 0 
in-person care 0.50 0.50 0 0.08 0.52 0.30 0.1 
 
Table 4.6: Summary of ICER Data 
Strategy Cost 
Incremental 
Cost Effect 
Incremental 
Effect Cost/Effect ICER 
Teleglaucoma  
Screening 871.54 
 
18.32 
 
47.57 
 in-person 
Screening 4441.42 3569.88 18.19 -0.12 244.05 (Dominated) 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
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Table 4.7: Accumulate Rewards, Costs, and Probabilities after 30 years 
 Cumulative 
Costs ($) 
Cumulative 
Rewards 
(QALY) 
Probability at each health state 
At-
Risk 
Mild Moderate Severe Blind 
Teleglaucoma 
1155.45 15.7 
3.71E-
05 
0.15 0.10 0.09 0.65 
In-person/ no 
screening 4035.19 16.8 
0 0.02 0.04 0.05 0.89 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
 
4.7 Figures 
Figure 4.1: Markov Model Transitional Health States  
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Figure 4.2: Cost-Effectiveness Analysis 
 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
 
Figure 4.3: Markov Probability Analysis of Health States 
 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
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Figure 4.4: DSA One-Way Sensitivity Analysis 
Figure 4.4a. Variable: Cost of blindness 
 
 
 
 
Figure 4.4b. Variable: Probability of Transitioning to Mild Stage Glaucoma 
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Figure 4.4c. Variable: Transitional Probability to Blind stage Glaucoma 
   
 
 
Figure 4.4d. Variable: Transitional Probability to Blind Glaucoma 
  
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
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Figure 4.5: Tornado Diagram for At-Risk Population 
 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
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Figure 4.6: Cost-Effectiveness Scatterplot 
 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
 
Figure 4.7: Acceptability Curve 
 
Footnote: Thomas S, Hodge WG, Malvankar-Mehta MS (2015). The Cost-Effectiveness Analysis 
of Teleglaucoma Screening Device. PLoS ONE (under second review 2015 June 7). 
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Chapter 5 Integrated Discussion 
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5.1 Overview 
This chapter outlines the thesis results, interpretations, and generates the 
thesis conclusions. In summary, the objectives of the thesis were (1) to 
determine the effectiveness of teleglaucoma in its capability to accurately 
discriminate between positive and negative cases and (2) to determine the cost-
effectiveness of teleglaucoma as a screening device.  
5.2 Integrated Discussion of Thesis Results 
This thesis synthesized published and unpublished research literature on 
the diagnostic accuracy of teleglaucoma. The meta-analysis found that the 
specificity and sensitivity were 0.79 [0.67, 0.88] and 0.83 [0.77, 0.88] 
respectively. The Canadian Ophthalmology Society (COS) criteria for the 
minimum effectiveness of tele-ophthalmology is a sensitivity of at least 80% and 
a specificity of at least 90%.1 Thus, according to COS standards teleglaucoma 
does not meet the minimum requirements for an effective screening tool. 
However, it is important to note that in comparison to the standard of care, 
teleglaucoma had a greater specificity than in-person examination, but was not 
as sensitive as in-person examination. Thus, although teleglaucoma does not 
meet Canadian standards, it is more effective than the current practice. 
Teleglaucoma demonstrated low false negative and high true positive 
rates. This is an indication of a good screening tool for glaucoma.2 Glaucoma is a 
progressive disease that becomes worst when untreated. False positive cases 
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are left untreated and may progress to advanced stages of the disease.2 For 
glaucoma specifically, it is important to detect the disease earlier to allow for 
early intervention and to prevent vision loss. Thus, this thesis has successfully 
demonstrated that teleglaucoma is beneficial to preventing visual impairment 
overall. However, the false positive rates are higher than in-person examination 
which seemingly introduces potential issues related to teleglaucoma.  
A false positive means a patient thinks they have the disease, when they 
actually do not. With some diseases such as cancer, the patient may experience 
depression and psychological stress as a response to their screening result. 
However, with glaucoma, because the disease progression is slowed with 
treatment, the likelihood of serious consequences is low. This in return removes 
the risk of serious patient psychological consequences. In addition, the 
confirmatory test for glaucoma occurs within two months which is a relatively 
short time for a patient to wait to confirm their disease status. Prior to screening 
the patient receives consultation on the consequences of test results to ensure 
the patient is informed and to minimize the physiological risks of false positives. 
The confirmatory diagnosis conducted by the ophthalmologist involves very 
minimal risks.2 Thus although, generally speaking a false positive is not good 
practice, with glaucoma there is very minimal risk to patient.       
In addition, the results were based on optimizing the use of several 
glaucoma diagnostic instruments for screening. Several studies have reported 
the differences in diagnostic accuracy based on the various combinations of 
diagnostic instruments. With greater amounts of diagnostic instruments used to 
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examine glaucoma patients, the higher the accuracy of the screening process. 
The instruments used in this analysis, which defined teleglaucoma, were based 
on the minimum requirements set by Canadian Medical standards.3      
In addition, teleglaucoma was able to detect greater proportions of 
glaucoma cases in comparison to in-person examination. This was an important 
finding as early detection plays an important role in preventing glaucoma 
progression. If caught early and treatment is initiated, glaucoma can be managed 
and patients can have preserved vision. The long term benefits of teleglaucoma 
found that in comparison to in-person examination, teleglaucoma prevents more 
cases of blindness.  
Blindness lowers one’s health-related quality of life (HRQoL) and limits 
one’s independence. As glaucoma progresses through its health states, the 
quality of adjusted life years (QALYs) declines. The “blindness” health state is 
represented by 0.5 QALYs whereas the “at-risk” health state is represented by 
0.87 QALYs.4,5 As glaucoma progresses to advance stages it also becomes 
more costly to manage and treat. Moreover, it is expected that if teleglaucoma 
detects more cases of glaucoma and at earlier stages, then blindness can be 
prevented. This study successfully found that teleglaucoma prevents 24% of 
cases, in the long term, in comparison to in-person examination. 
The second section of this thesis examined the cost implications of 
teleglaucoma. The direct and indirect costs of teleglaucoma system, which were 
synthesized systematically through the meta-analysis, were applied to the 
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Markov Model. The costs and the measure of quality of life of each health states 
were included in the analysis. Through the meta-analysis, the effectiveness of 
teleglaucoma was measured in specificity and sensitivity and was applied to the 
Markov Model. When taking all costs into consideration, teleglaucoma displayed 
reduction of costs.  Furthermore, in terms of the effectiveness of teleglaucoma, 
this thesis found that teleglaucoma added 0.12 QALYs per each patient 
screened. This is a significant improvement in HRQoL when taking into 
consideration the time frame. The analysis used an annual time frame and all 
costs and benefits are thus based on yearly outcomes. Therefore, although a 
0.12 QALY increase may not be a large impact over many years, a 0.12 QALY 
increase per year is a substantial difference in HRQoL. In conclusion, it was 
found that teleglaucoma is more cost-effective than in-person examination. 
5.3 Thesis Limitations and Knowledge Gaps in Current 
Literature 
There were limitations within this thesis study. The systematic review 
included studies written in English only. By excluding potential articles based on 
language, this may bias the results. It would essentially produce results valid to 
English speaking countries mainly. Statistically, this reduces sample size, 
whereby limiting the power of the results.  
The quality of the study evidence varied and despite variation, all studies 
were included in the systematic review and meta-analysis. The quality of 
evidence was based on the risk of bias, imprecision, inconsistency, and 
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indirectness.6-11 Of the 45 studies included in the systematic review, only 17 were 
of high quality based on the GRADE guidelines. High quality studies are those 
that have a high confidence that the true effect lies close to that of the estimate 
effect based on the fact there is no or minimal bias.6-11 Thus, the majority of 
studies provided quality of evidence which were of low or moderate levels. The 
quality of evidence limits the validity of the results and thus, in return limits the 
accuracy of the synthesized results.  
The meta-analysis section took into account the sample size and standard 
errors of each study which minimizes the risk of bias. However, all studies were 
observational studies and this reduces the quality of evidence. Observational 
studies lack a controlled environment and patients are not necessarily 
randomized.12 This reduces the confidence that the treatment intervention is 
responsible for the differences in results. In contrast, randomized control trials 
(RCT) provide high level quality of evidence and due to gaps in the research 
literature; no RCTs have been conducted on teleglaucoma.12,13 Observational 
studies provide a moderately good level of evidence, however they cannot 
control for all factors that may influence the study results. This indicates the need 
for more RCTs on this topic. Nonetheless, as the effectiveness of teleglaucoma 
includes the healthcare service quality, it is beneficial to highlight the 
teleglaucoma service in real-time through observational studies. 
In addition, there was variability in the clinical characteristics reported by 
studies. Some studies focused on the specificity and sensitivity of teleglaucoma 
only and did not include a comparator. Some studies used various technologies 
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as part of their teleglaucoma system. There is expected variation in the 
technology quality and to minimize bias, only current studies were included.   
  Another limitation of the systematic review is the sample size. There were 
only ten studies used in the meta-analysis section. Of those ten studies, only five 
compared teleglaucoma to a comparator. When conducting a systematic review, 
the larger the sample size, the more evidence it will provide. Sample size is 
important for statistical reasons. For instance, the smaller the sample size, the 
more standard error and the lower the power of the results.14 It also limits the 
confidence in the results. Thus, a sample size of ten is fairly small. Unfortunately, 
systematic reviews are dependent on the literature. Although, a comprehensive 
systematic search of published and unpublished literature was conducted, the 
results may not be representative of the actual service quality due to research 
gaps in literature. This suggests more literature is required on the effectiveness 
of teleglaucoma in general, and also on teleglaucoma in comparison to in-person 
examination. 
Common bias affecting systematic reviews is publication bias which is the 
selective publication of certain types of studies.12 To minimize publication bias, 
published and unpublished research databases were searched and articles from 
both sources were included. Thus, from the assessment, publication bias was 
minimal in this systematic review.      
There were a few assumptions made during the CEA that may limit the 
external validity of this thesis. The main limitation is the study population; this 
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analysis applies only to rural populations, more specifically rural Alberta. 
Therefore, all costs, the healthcare system model, glaucoma prevalence, and 
patient demographics derived were based on Alberta. Importantly, the distance 
required for patients to travel is based on distances in Alberta. The cost-
effectiveness of teleglaucoma is highly dependent on patient savings from the 
reduction in travel distance, time, and costs. Thus, the external validity of the 
study is restricted to populations similar to Alberta. In order to determine if 
teleglaucoma is cost-effective for a specific area, a CEA based on that specific 
population is required, as distances, currencies, and patient demographics 
change according to area. Importantly, the prevalence of glaucoma in the study 
population effects the cost-effectiveness. If the prevalence of glaucoma is higher, 
teleglaucoma becomes more cost-effective. This thesis assumed a prevalence of 
glaucoma found in Alberta, which may or may not be similar to other provinces or 
populations.  
 There was limited access to official costing sources such as specific 
Alberta hospital budgets. Thus, the actual costs for servicing a teleglaucoma 
clinic in its totality could not be determined accurately. Labour costs were 
estimated based on average Alberta physician and healthcare provider incomes. 
The costs used in the analysis were derived from published data and expert 
opinion. Thus, the total fixed and variable costs are estimates based on quotes 
from research literature required to service a teleglaucoma system. Some of the 
research literature were Canadian, but the majority of costing sources were 
European or American studies which may not represent Alberta best. Because of 
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the lack of official data sources, this thesis made assumptions that the costs 
would be similar in Alberta. Where possible, hospital data from London, Ontario 
from 2014 was used to at least have current and Canadian data. Examples of 
these estimates were the costs of ophthalmic instruments. Likewise, the costs of 
the comparator intervention were also derived from estimates, quotes, and 
published data which may not accurately represent Alberta. These limitations and 
resulting assumptions can create some inaccuracies in the results of the CEA 
and the internal validity of the costing analysis. It can bias the results in either 
way: cause teleglaucoma to become more cost-effective or in-person 
examination to become more cost-effective.  
From the thesis results, a large proportion of teleglaucoma cost-savings 
was attributed to the reduction in direct patient costs (travel and wait times). 
Although travel times and wait time were sourced from published research 
literature based on Alberta’s population, there were some limitations in the 
translation of data into costs. Firstly, only a few studies reported the travel 
distances and wait times, thus the power was limited by sample size. Secondly, 
the conversion of wait times and travel times into productivity loss was based on 
the assumption that patients were employed and earned an average Alberta 
salary. Glaucoma is a disease of the elderly and a proportion of patients may not 
be employed, but rather retired. The employment status and exact salaries of 
glaucoma patients at the Alberta teleglaucoma clinics are inaccessible and thus 
estimates had to be used.  
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Nevertheless, this raises an important issue of value of patient’s time. 
Although, the patient is unemployed and may not have employment income, 
firstly, they may have income from other sources (such as pensions, RRSPs, or 
investment incomes). These sources of income are private data and may not be 
reported in literature.15 As a result, income from other sources are challenging to 
quantify and estimate. Secondly, based on the Grossman model, it can be 
argued that those who are unemployed should not have the same monetary 
value as employed people and rather have a lower monetary value.16 This is 
ethically incorrect because a person’s time is valuable with or without 
employment. Additionally, the value of the time spent by the unemployed cannot 
be assumed to be less than the value of the time of the employed.16 The 
unemployed, retired, and disable proportions of the study population although 
may not work, but their time still has equal value as any other employed person. 
Thus, when placing a monetary value on the study population it was important to 
consider this and to not treat any group differently. Given these challenges and 
reasons, the assumption to place the average wage salary as the monetary value 
of the patient’s time was the best solution as it was most practical and just option.  
A simplified model of productivity loss was used which included solely 
employee wages. The costing model did not include other measures of 
productivity, nor societal costs and indirect patient costs such as the 
psychological costs or opportunity costs. Furthermore, patient compensation 
resources such as health insurance model were not incorporated into the costing 
models. Therefore, these estimates can bias the thesis results and create 
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limitations to the internal validity of the cost-effectiveness analysis. Fortunately, 
to minimize these inaccuracies, sensitivity analysis were performed. However, to 
improve this thesis, a full costing evaluation of current teleglaucoma service 
using precise sources is recommended.       
Similarly, the probabilities were derived from research literature and expert 
opinion and assumptions were made in order to derive the estimated 
probabilities. For example, the transitional probabilities assumed patients were 
either treated or untreated irrespectively at the same rate. That is, the probability 
a patient will transition to another glaucoma health state when “treated” assumed 
75% patient’s compliance with treatment at all health states. Whereas “untreated” 
implied patients receive no treatment at all health states. Since the transitional 
probabilities may differ based on treatment paradigms used, uncertainties can 
develop. Likewise, the Markov Model probabilities are influenced by many 
factors. Estimates and derivations of the probabilities of each of these factors 
increases the likelihood of uncertainties and thus can bias the thesis results. 
Lastly, the outcome measure used in the analysis was costs per QALY 
gained ($/QALY). Although this is a universal measure that allows standardized 
comparison across healthcare disciplines, it is acknowledged that there may be 
other useful outcome measures. “Costs per detected case” allows a more 
immediate measure of the direct benefits of teleglaucoma. This outcome 
measure can be more practical for clinicians and healthcare administrators; it is 
easier to understand and apply to daily clinical practice. It allows direct 
comparison among programs which have the same goals.17 For future research, 
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it is recommended to add the “cost per detected case” measure to obtain the 
immediate benefits and costs to the healthcare system. Immediate outcome 
measures are useful for health policy decision-makers as it provides a simple 
decision criterion for resource allocation without the consideration of many 
uncertainties related to calculating long-term benefits.17 Although, “costs per 
detected case” is a tangible outcome measure, unlike “$/QALY”, it excludes 
quality of life measures and may not capture all important benefits. 
Consequently, in addition to “$/QALY”, “costs per detected case” is a useful 
outcome measure to enhance the cost-effectiveness analysis of teleglaucoma.  
5.4 Conclusions and Future Directions 
In conclusion, this thesis has found teleglaucoma is more specific and less 
sensitive than in-person examination and it is more cost-effective screening 
device for glaucoma in rural populations. To optimize the results, there are 
several recommendations for future study directions. Future studies can examine 
the use of teleglaucoma in semi-urban and urban areas; its potential benefits and 
its cost-effectiveness. The main advantage of teleglaucoma in rural populations 
is the convenience and the reduction in patient travel costs. However, 
teleglaucoma can play a role in urban populations. Urban hospitals can be 
overflown with patients placing a burden on the healthcare system and 
prolonging patient wait times. Teleglaucoma can act to reduce patient load at the 
hospital and therefore, improve the efficiency of ophthalmology clinics. It is 
speculated that there will be cost-savings with the implementation of 
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teleglaucoma in urban settings, and teleglaucoma can be cost-effective in these 
settings as well. Direct benefits are expected from the decline of patient load at 
ophthalmic clinics, which translates into reduced patient wait times and minimize 
unnecessary ophthalmic visits. However, the cost-effectiveness in urban, cities 
such as Calgary or Edmonton, may not be as comparable to that of rural Alberta, 
because the main cost-savings found in rural areas was the reduction of patient 
costs due to reduced travel distances and times. In urban cities, there are more 
ophthalmic centers and increased access to ophthalmic care in comparison to 
rural areas. Thus urban patients may not have to travel as far to receive 
ophthalmic care. Nonetheless, urban cities are more populated than rural cities. 
From an economic perspective, this is beneficial as it would allow the service to 
reach a greater population. Consequently, future studies are needed to examine 
the use of teleglaucoma in urban populations and its cost-effectiveness. And 
when comparing implementation in either setting (urban or rural) special caution 
needs to be taken with regards to ethical resource allocation based on equity 
versus efficiency and demand versus need.          
This thesis has identified gaps in literature which can help guide future 
studies. There is demand for randomized controlled trials on teleglaucoma to 
provide high quality of evidence. More comparative studies are required which 
analyze teleglaucoma against a comparator, specifically in-person examination, 
the standard of care. Future studies can examine the long term benefits of 
teleglaucoma. Most studies included in the thesis analysis examined the benefits 
of teleglaucoma directly after screening and long term benefits were not included. 
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Glaucoma is a chronic, progressive disease affecting the elderly and has long 
term consequences if not managed appropriately. Thus, more studies analyzing 
the long term benefits of screening are beneficial to patient outcomes.  
In addition, future reviews and CEAs should examine the use of 
teleglaucoma systems within optometrist or pharmacist clinics. These clinics are 
pre-established within rural areas and are usually more abundant than 
ophthalmologist clinics. Placement of teleglaucoma systems within optometrist or 
pharmacist clinics can reduce overhead costs and essentially prove to be even 
more cost-effective.      
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Appendix 2: Systematic Review Search Strategies 
DATABASE  SEARCH TERMS 
OVID Medline   
1 Exp Glaucoma/ OR Intraocular Pressure/ OR Ocular 
hypertension/ 
2 Glaucoma* OR Intraocular pressure OR Intra-ocular pressure 
OR Intraocular hypertension OR Intra-ocular hypertension OR 
Intra-ocular tension OR Intraocular tension OR Ocular 
hypertension OR Ocular tension OR Eye tension OR Eye 
pressure 
3 1 OR 2 
4 Remote consultation/ OR Telemedicine/ OR Telepathology/ 
OR Mobile Health Units/ OR Community Pharmacy Services/ 
5 Automated detection OR Teleglaucoma OR Telescreen* OR 
Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR 
Telemedicine OR Tele-medicine OR digital indirect 
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR 
Teleconsult* OR Tele-consult* OR Telediagnos* OR Tele-
diagnos* OR Telehealth OR Tele-health OR Mobile health OR 
eHealth OR Automated Perimetry Exam* 
6 4 OR 5 
7 Diagnosis/ OR Early diagnosis/ OR Diagnostic Techniques, 
Ophthalmological/ OR Tonometry, Ocular/ OR Diagnosis.fs. 
OR Vision screening/ OR Mass screening/ OR Visual Field 
Tests/ 
8 Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr* 
OR Campimetr* OR Visual field test* OR 
Oculplethysmograph* OR Vision test* OR Early diagnosis 
9 7 OR 8  
10 3 AND 6 AND 9 
RESULTS 86 
 Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, 
Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present 
OVID EBMASE  
1 Exp glaucoma/ OR Intraocular pressure abnormality/ OR 
Intraocular pressure/ 
2 Glaucoma* OR Intraocular pressure OR Intra-ocular pressure 
OR Intraocular hypertension OR Intra-ocular hypertension OR 
Intra-ocular tension OR Intraocular tension OR Ocular 
hypertension OR Ocular tension OR Eye tension OR Eye 
pressure 
3 1 OR 2 
4 Telemedicine/ OR Telehealth/ OR Telediagnosis/ OR 
Telepathology/ OR Teleconsultation/ OR Telemonitoring/ OR 
computer assisted perimetry/ 
5 Automated detection OR Teleglaucoma OR Telescreen* OR 
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Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR 
Telemedicine OR Tele-medicine OR digital indirect 
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR 
Teleconsult* OR Tele-consult* OR Telediagnos* OR Tele-
diagnos* OR Telehealth OR Tele-health OR Mobile health OR 
eHealth OR Automated Perimetry Exam* 
6 4 OR 5 
7 diagnosis/ OR early diagnosis/ OR diagnostic accuracy/ OR 
diagnostic test accuracy study/ OR diagnostic value/ OR 
perimetry/ OR oculoplethysmography/ OR vision test/ 
8 Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr* 
OR Campimetr* OR Visual field test* OR 
Oculplethysmograph* OR Vision test* OR Early diagnosis 
9 7 OR 8  
10 3 AND 6 AND 9 
 Embase Classic+Embase 1947 to 2014 March 11 
CINAHL  
1 (MH "Glaucoma+") OR (MH "Ocular Hypertension") OR (MH 
"Intraocular Pressure") 
2 Glaucoma* OR Intraocular pressure OR Intra-ocular pressure 
OR Intraocular hypertension OR Intra-ocular hypertension OR 
Intra-ocular tension OR Intraocular tension OR Ocular 
hypertension OR Ocular tension OR Eye tension OR Eye 
pressure 
3 1 OR 2 
4 (MH "Telehealth") OR (MH "Telemedicine") OR (MH "Remote 
Consultation") OR (MH "Telepathology") OR (MH "Mobile 
Health Units") 
5 Automated detection OR Teleglaucoma OR Telescreen* OR 
Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR 
Telemedicine OR Tele-medicine OR digital indirect 
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR 
Teleconsult* OR Tele-consult* OR Telediagnos* OR Tele-
diagnos* OR Telehealth OR Tele-health OR Mobile health OR 
eHealth OR Automated Perimetry Exam* 
6 4 OR 5 
7 (MH "Diagnosis") OR (MH "Diagnostic Services") OR (MH 
"Diagnosis, Eye") OR (MH "Tonometry") OR (MH "Vision 
Screening") OR (MH "Vision Tests") OR (MH "Perimetry") OR 
(MH "Early Diagnosis")  
8 Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr* 
OR Campimetr* OR Visual field test* OR 
Oculplethysmograph* OR Vision test* OR Early diagnosis 
9 7 OR 8  
10 3 AND 6 AND 9 
Cochrane, 
Web of 
 
1 Glaucoma* OR Intraocular pressure OR Intra-ocular pressure 
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Science, 
BIOSIS, 
Dissertations 
and Thesis, 
Canadian 
Health 
Research 
Collection 
OR Intraocular hypertension OR Intra-ocular hypertension OR 
Intra-ocular tension OR Intraocular tension OR Ocular 
hypertension OR Ocular tension OR Eye tension OR Eye 
pressure 
2 Automated detection OR Teleglaucoma OR Telescreen* OR 
Teleophthalm* OR Tele-ophthalm* OR Tele-glaucoma OR 
Telemedicine OR Tele-medicine OR digital indirect 
ophthalmoscop* OR Telemonitor* OR Tele-monitor* OR 
Teleconsult* OR Tele-consult* OR Telediagnos* OR Tele-
diagnos* OR Telehealth OR Tele-health OR Mobile health OR 
eHealth OR Automated Perimetry Exam* 
3 Diagnos* OR Screen* OR Tonomet* OR Detect* OR Perimetr* 
OR Campimetr* OR Visual field test* OR 
Oculplethysmograph* OR Vision test* OR Early diagnosis 
4 1 AND 2 AND 3 
Footnote:  
1. Thomas, Sera-Melisa; Jeyaraman, Maya; Hodge, William G.; Hutnik, Cindy; Costella, John; 
Malvankar-Mehta, Monali S. (2014): The Effectiveness of Teleglaucoma versus In-Patient 
Examination for Glaucoma Screening: A Systematic Review and Meta-Analysis. Table_S1.docx. 
PLOS ONE. 10.1371/journal.pone.0113779.s001. Retrieved 16:24, Jan 20, 2015 (GMT). 
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Appendix 3: Hierarchical Logistic Regression Results 
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Appendix 4: Markov Model Decision Tree 
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Appendix 5: Estimated Direct Costs to Patients 
 
Source 
 Unit $/unit Cost ($) 
 Teleglaucoma    
CBC, 2014
1 
Travel distance (km) 0 $1.264/Liter*0.0
89L/km 
0 
 
StatsCan, 
2013
2 
Travel time (hour) 0 $29.54/hr 0 
Duration of Doctor visit 
(hour) 
1.3
 
$29.54/hr 38.40 
Absence from work 
(hour) 
3.3
 
$29.54/hr 97.48 
   TOTAL 135.88 
 In-person Care     
CBC, 2014
1 
Travel distance (km) 4906
 
$1.264/Liter 
x0.089L/km 
551.90 
 
StatsCan, 
2013
2 
Travel time (hour) 61.23 $29.54/hr 1808.73 
Duration of Doctor visit 
(hour) 
1.91 $29.54/hr 56.6 
Absence from work 
(hour) 
6.6 $29.54/hr 194.96 
   TOTAL 2612.19 
Footnote: 
1. Canadian Broadcasting Corporation (CBC). (2014). Alberta Gas Prices. Available: 
http://www.cbc.ca/calgary/features/gasprices/ Accessed 2014 Mar 3. 
2. Statistics Canada (StatsCan) (2014). Earnings, average weekly, by province and territory. Available 
online <http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr79-eng.htm> 
Accessed 2014 Mar 3. 
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Appendix 6: Total Cost Data (Cost per patient serviced) 
Cost Type Parameters Included Teleglaucoma in-person 
Combined Practice 
(Teleglaucoma + in-
person) 
Initial  Fixed costs 41.87 2.39 44.26 
Incremental Patient costs, service 
costs, labour, 
855.38 57809.74 58665.12 
 
Appendix 7: Distribution for Probabilistic Sensitivity Analysis 
 
 
 
 
 
 
 
 
 
Index Variable Name Type Param 1 Param 2 Sample Rate Option Help/Explanation
1 dist_cost_blind Gamma 34.5 0.001 0 Param 1 = alpha; Param 2 = lambda
2 dist_cost_inpat_incr Gamma 95.2 0.03 0 Param 1 = alpha; Param 2 = lambda
3 dist_cost_inpat_initial Gamma 1 0.00003 0 Param 1 = alpha; Param 2 = lambda
4 dist_cost_tele_initial Gamma 99.2 0.085 0 Param 1 = alpha; Param 2 = lambda
5 dist_cost_tele_incr Gamma 89.2 0.8 0 Param 1 = alpha; Param 2 = lambda
6 dist_probAtrisktomild_no_txt Beta 64.2 41 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
7 dist_prob_atrisktomild_txt Beta 75.2 45.3 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
8 dist_prob_mildtomod_txt Beta 89.63 78.21 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
9 dist_prob_mildtomod_no_txt Beta 88.21 165.23 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
10 dist_prob_mod2sev_no_txt Beta 98.22 54.22 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
11 dist_prob_modtosev_txt Beta 54 7.52 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
12 dist_prob_sev3blind_no_txt Beta 29.336 170.253 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
13 dist_prob_sev2blind_txt Beta 30.582 180.42 0 2 Param 1 = alpha; Param 2 = beta. Option: 1 = Integer parameters only; 2 = Real-numbered parameters
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Appendix 8: Derivation of Costs for teleglaucoma and in-person care 
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Footnote: 
1.  Tuulonen A, Ohinmaa A, Alanko H, et al. (1999) The application of teleophthalmology in examining 
patients with glaucoma: a pilot study. J Glaucoma 8: 367–73. 
2. Bank of Canada. (2014) Daily Currency Converter. Available: 
http://www.bankofcanada.ca/rates/exchange/daily-converter/. 
3. Statistics Canada (StatsCan) (2014). Earnings, average weekly, by province and territory. Available 
online <http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/labr79-eng.htm> 
4. Government of Alberta (2014). Medical Procedures Lists. Available online: 
<http://www.health.alberta.ca/documents/SOMB-Medical-Procedures-2014-04.pdf> 
5. Thomas S-M, Jeyaraman MM, Hodge WG et al. (2014) The Effectiveness of Teleglaucoma versus 
In-Patient Examination for Glaucoma Screening: A Systematic Review and Meta-Analysis. PLoS 
ONE 9(12): e113779. doi: 10.1371/journal.pone.0113779. pmid:25479593 
6. Arora S, Rudnisky C, Damji K (2014) Improved Access and Cycle Time with an “In-house” patient-
centered teleglaucoma program versus traditional in-person assessment. Telemed J E-Health 
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Appendix 9: Costs Associated with each health state  
Glaucoma Stage 
Costs 
($/patient) 
 
Author 
0 623 Lee, 20061 
1 1480 
2 1765 
3 1917 
4 2464 
5 2511 
Health State 
 
Derivative Costs 
($/patient) 
Author 
At-Risk  = Stage 0 costs 623 Lee, 20061 
Mild Glaucoma = Stage 1 costs  1480 
Moderate 
Glaucoma 
= Stage 2 + Stage 3 Costs 3682 
Severe Glaucoma = Stage 4 + stage 5 costs  4975 
Blindness = $2,613M (total costs of vision loss in Alberta)  
x 77,615 people with vision loss in Alberta) 
33666 CNIB, 20082 
Footnote: 
1. Lee PP, Walt JG, Doyle JJ, et al. A Multicenter, Retrospective Pilot Study of Resource Use and 
Costs Associated With Severity of Disease in Glaucoma. Arch Ophthalmol. 2006;124(1):12-19. 
doi:10.1001/archopht.124.1.12. 
2. CNIB and the Canadian Ophthalmology Society. (2008) Costs of vision loss in Canada: Summary 
report. Available online: 
http://www.cnib.ca/eng/CNIB%20Document%20Library/Research/Summaryreport_Covl.pdf 
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